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Putative Role of Palmitate and Akt signaling in Attenuating Skeletal Muscle Growth in the 
Obese Zucker Rat 
 
Jonathan Michael Peterson, BS, MS 
 
The Obese zucker rat (OZR) is a model of obesity and metabolic syndrome, with a 
reduced skeletal muscle mass compared with the lean zucker rat (LZR). Growth and hypertrophy 
of muscle fibers critically depend on activation and differentiation of satellite cells into new 
myonuclei, as well as the prevention of myonuclear apoptosis. Akt is known to regulate satellite 
cell activation and differentiation and inhibit apoptotic signaling. Akt activity is also reduced in 
the OZR compared to the LZR. The present study had two primary purposes; first, to observe, in 
vitro, the effects of the saturated free fatty acid palmitate on C2C12 mouse myoblast 
proliferation and differentiation, Akt signaling and apoptosis in myotubes, and second, to 
examine if there was reduced Akt signaling, satellite cell proliferation and differentiation, and/or 
increased satellite death in the OZR compared to the LZR.  Akt signaling was significantly 
reduced both in vitro following palmitate treatment and in vivo in the OZR.  Furthermore, 
myoblast proliferation and differentiation were reduced after palmitate treatment, in vitro, and 
satellite cell activation was reduced in the OZR compared to the LZR.  Although palmitate 
treatment was sufficient to induce apoptotic signaling in C2C12 myotubes, there was no increase 
in apoptotic signaling in muscles of the OZR.  Together, these data indicate that although 
disruptions in Akt signaling in muscles of the OZR may be responsible for the decrease in 
muscle mass through attenuated satellite cell activation and proliferation, increased apoptotic 
signaling does not appear to be a factor to explain the decrease muscle mass in the OZR 
compared to the LZR. 
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Metabolic syndrome is a clinically important problem, which affect more than 50 million 
Americans (11). Metabolic syndrome is defined as a cluster of risk factors for heart disease and 
type 2 diabetes mellitus including: (i) obesity, (ii) insulin resistance (with or without glucose 
intolerance), (iii) hypertension, (iv) dyslipidemia, (v) a prothrombotic state (e.g., high fibrinogen 
or plasminogen activator inhibitor–1 in the blood), and (vi) a proinflammatory state (e.g., 
elevated C-reactive protein in the blood). Disruptions of glucose or fatty acid oxidation are major 
contributors to the complications associated with obesity and metabolic syndrome. Because 
skeletal muscles are the primary tissue responsible for glucose and fatty acid oxidation (2; 3; 23), 
any reduced skeletal muscle mass would be an unfavorable outcome in metabolic syndrome. 
The obese Zucker (fa/fa) rat (OZR) is a rodent model of severe obesity and metabolic 
syndrome.  The OZR has a dysfunctional leptin receptor which leads to chronic hyperphagia, 
resulting in a rapid onset of  obesity, skeletal muscle insulin resistance, hyperglycemia, mild 
hypertension, and high circulating levels of free fatty acids (12; 26; 27; 30). Although OZRs are 
significantly less active than the LZRs (5),  OZRs have a greater body mass, and therefore should 
have a greater stimulus for muscle growth on the weight bearing muscles.  However, there is a 
significant (10-25%) reduction in the skeletal muscle mass of the OZR compared to the lean 
Zucker rat (LZR) phenotype (10). We have found that increasing the activity of the OZR through 
daily treadmill running, fails to increase the size of skeletal muscles (12). This raises the 
possibility that a metabolic syndrome induced defect in skeletal muscle may account for the 
reduction in skeletal muscle mass in the OZR.   
Hypertrophy of muscle fibers critically depends on the activation and differentiation of 
satellite cells into new myonuclei, as well as the preservation of mature myonuclei (1; 17; 21; 22; 
viii 
 
24). It is possible that disruptions in the regulation of myonuclear number may account for the 
reduced muscle mass in the OZR compared to the LZR, as muscle fiber size is critically 
dependent on myonuclear content (1; 24). This idea is consistent with the observation that  
nucleic acid content is less in the OZR, (10) which could be explained if there was a decreased 
myonuclear number, in the skeletal muscles of OZRs compared to the LZRs.   
One potential mechanism that might account for reduced nuclei is lower Akt activity in 
muscles of the OZR (20). This is because Akt regulates at least in part, satellite cell activation 
and differentiation, and  inhibits myonuclear apoptosis (4; 8; 9; 13-15; 18; 19; 25; 28; 29).  Akt 
activity might be inhibited by high intramuscular lipid levels in muscles of animals with 
metabolic syndrome, such as palmitate (6; 7), which is the most common saturated fatty acid 
found in the muscle tissue (16).   Our central hypothesis is that increased palmitate decreases 
satellite cell proliferation and differentiation and sensitizes differentiated myonuclei to 
apoptosis through disruptions in Akt signaling. This central hypothesis was tested by the 
following four specific aims.  
 
Specific aim 1: To determine if the addition of palmitate attenuates proliferation and 
differentiation of myoblasts in vitro. 
Hypothesis 1.1: Palmitate treatment of C2C12 myoblasts will decrease myoblast 
proliferation in vitro.    




Specific aim 2: To determine if reduced proliferation and differentiation of satellite cells 
contributes to a decreased muscle fiber size and muscle wet weight in the OZR model of obesity 
and metabolic syndrome.  
Hypothesis 2.1:  The number of activated satellite cells incorporated into myofibers in 
vivo will be lower in muscles of OZR rats compared to LZR. 
Hypothesis 2.2: Impaired satellite cell proliferation cannot be restored by increased 
loading in skeletal muscles of OZR compared to the LZR. 
   
Specific aim 3: To determine if palmitate treatment increases the susceptibly of myoblasts or 
myotubes to mitochondrial-associated apoptosis in vitro. 
Hypothesis 3.1: Palmitate treatment will increase nuclear apoptosis of C2C12 myoblasts 
and myotubes through mitochondrial-associated (intrinsic) pathways including an 
elevation of the Bax to Bcl2 ratio. 
 
Specific aim 4: To determine if metabolic syndrome increases the susceptibly of myonuclei to 
apoptosis during muscle wasting induced by denervation.  
Hypothesis 4.1: Mitochondrial associated apoptotic signaling and nuclear apoptosis will 
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Clinical significance of metabolic syndrome and obesity.  
The results of the National Health and Nutrition Examination Survey 2003-2004 indicate 
that an estimated two-thirds of U.S. adults are either overweight or obese, and the prevalence of 
obesity is increasing, especially in young people, affecting approximately 17% of Americans 2-
19 years of age (18; 60; 61). With increased obesity there is an elevation of lipids in the 
bloodstream, termed lipidemia, which is a major risk factor for the development of metabolic 
syndrome and heart disease, the number one cause of death in the U.S. (59). Metabolic syndrome 
is defined as a cluster of risk factors for heart disease and type 2 diabetes mellitus including: (i) 
obesity, (ii) insulin resistance (with or without glucose intolerance), (iii) hypertension, (iv) 
dyslipidemia, (v) a prothrombotic state (e.g., high fibrinogen or plasminogen activator inhibitor–
1 in the blood), and (vi) a proinflammatory state (e.g., elevated C-reactive protein in the blood). 
Muscle strength negatively correlates with the development of metabolic syndrome regardless of 
age or BMI (39). Moreover, the quality of muscle (strength normalized to cross sectional area) is 
significantly reduced in skeletal muscle of persons with obesity and metabolic syndrome (13; 
64). Combined, these data indicated that there may be an interaction between obesity and 
metabolic syndrome and skeletal muscle regulation.   
 
Importance of skeletal muscle in metabolic syndrome and obesity.  
Fasting and postprandial free fatty acid concentrations are elevated in individuals who are 
obese or who have metabolic syndrome (31). Thus, insulin target tissues, such as skeletal muscle, 
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are constantly exposed to high levels of FFAs. Skeletal muscle is the primary tissue for glucose 
and lipid utilization and has become an important target tissue in the study of metabolic 
syndrome as it accounts for 55-100% of glucose intolerance (5; 6; 63).  Attenuated muscle mass 
associated with obesity and metabolic syndrome could be particularly detrimental as blood 
glucose and lipid levels increase and the ability to utilize each is diminished. For example, the 
obese zucker rat (OZR) is a model of obesity and metabolic syndrome based on chronic 
hyperphagia (8), which results in the rapid development of obesity, insulin resistance, and 
hyperlipidemia (4; 8; 11; 41). Within the OZR, there is a significant (10-25%) reduction in the 
skeletal muscle mass compared to the Lean Zucker rat (LZR) phenotype (25).   
 
Nuclear regulation of muscle mass.  
  Each myonucleus controls a relatively fixed cytoplasmic area, so growth or hypertrophy 
of a muscle fiber is critically dependent on adding new nuclei (1; 34). Muscle satellite cells are 
quiescent myogenic precursor cells found between the basal lamina and the sarcolema of a 
muscle fiber (34) and they provide the only important means of adding new nuclei to adult 
muscle (1; 33; 55; 62; 67). In contrast, apoptosis, or programmed cell death, can selectively 
eliminate myonuclei and satellite cells, and can lead to skeletal muscle atrophy (1; 2; 24; 50).   
 
 AKT regulation of muscle in obesity and metabolic syndrome.  
  Protein Kinase B/Akt (Akt) is a family of serine/threonine-specific protein kinases. Two 
Akt isoforms are highly expressed in skeletal muscle (Akt1 and Akt2). When Akt is 
constitutively activated there is an increase in muscle hypertrophy and a corresponding decrease 
in the amount of free fatty acids and adipose tissue (46).  On the other hand, when Akt activity is 
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reduced there is a corresponding reduction in free fatty acid metabolism and muscle mass (7).  
Paradoxically, Akt activity can be inhibited by chronic exposure to certain free fatty acids, such 
as palmitate (14; 15), and has been shown to be attenuated with obesity and metabolic syndrome 
(16; 43; 45; 75). Additionally, in the OZR, Akt activity is reduced and there is a decreased 
nucleic acid content in the skeletal muscles, compared to the LZR (25; 43), further demonstrating 
that decreased Akt activity with obesity and metabolic syndrome may be involved with 
attenuated skeletal muscle of these animals. 
 
Akt regulation of cell cycle progression and satellite cell proliferation. 
Disrupted Akt signaling with obesity and metabolic syndrome may impair satellite cell 
proliferation. Akt signaling is integrally involved in the regulation of satellite cell proliferation 
and differentiation by controlling cell cycle progression (7; 17; 23; 26; 27; 29; 36; 37; 74; 78; 
80). The progression of the cell cycle is as follows: (i) First the cell begins in the G1 phase of the 
cell cycle, containing one copy of DNA, (ii) next, DNA replication begins, the S-phase, (iii) 
thirdly, the G2 phase in which the cell has two copies of DNA but has not yet divided, (iv) the 
final stage of the cell cycle is the M-phase in which the cell begin mitosis, (v) and the cell cycle 
is completed with the formation of two new ‘daughter’ cells and begins again in G1 (44). Akt is a 
key regulator of cell cycle progression by exerting control at check points G1 and G2 in the cell 
cycle. 
 Akt may control satellite cell progression through cell cycle progression via the cyclin-
dependent kinase inhibitor p21 in (3; 36; 56; 70; 71).  As diagramed in figure 1, when in the 
nucleus, p21 inhibits cell proliferation, however when phosphorylated by Akt, p21 protein leaves 
the nucleus and is no longer able to interfere with cell cycle progression (32; 47; 48; 72).  
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Additionally, Akt signaling can enhance proliferation of satellite cells by down-regulating the 
negative inhibition of forkhead (FoxO) transcription factor FoxO3a (3; 28; 52).  When 
phosphorylated by Akt, FoxO3a leaves the nucleus and removes the inhibition of FoxO3a on 
myogenic regulatory factors, like MyoD, and other cell cycle proteins (3; 27; 28; 38; 54). Akt 
can also enhance cell cycle progression  of satellite cells through regulation of the activity of 
cyclin D in the G1-phase and cyclin B1 during the G2/M phase transition (38; 65; 71).  





Figure 1. A schematic representation of Akt action on cell cycle control. 
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AKT regulation of satellite cell differentiation. 
After proliferation, satellite cells must differentiate and become incorporated into existing 
muscle fibers. Satellite cell differentiation is  a highly controlled process (49) that is dependent 
on the myogenic regulatory factors, MyoD and myognein, and Akt activity. MyoD and 
myogenin are muscle-specific helix-loop-helix transcription factors which regulate muscle 
specific genes (9; 34; 53; 58).  As diagramed in figure 2 it appears that Akt is transcriptionally 
regulated by MyoD, and provides a positive feedback to enhance the actions of MyoD to further 
increase its own transcription (19; 37; 40).  Furthermore, Akt also works in conjunction with 
MyoD to promote the transcription of myogenin (40), a necessary step for the progression of 
muscle cell differentiation (7). Akt, particularly the Akt2 isoform, is essential for differentiation 
to occur.  When the expression of Akt2 is inhibited in C2C12 myoblasts, an in vitro model of 
muscle satellite cells, there is complete abolishment of differentiation (7; 40).  Additionally, Akt 
knockout mouse have much smaller muscles than their wildtype counterparts (16; 17), whereas, 
over-expression of active Akt induces skeletal muscle hypertrophy (46).   




Figure 2: A schematic representation of Akt action and Myoblast differentiation. 
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Akt and myonuclear apoptosis.  
Loss of myonuclei via apoptosis is a potential mechanism that could contribute to lower 
muscle mass in obesity and metabolic syndrome. As diagramed in figure 3, Akt has been shown 
to inhibit apoptosis through a number of pathways (23; 81).   Activated Akt inhibits the activity 
of the Bcl-associated death promoter (BAD) protein (20).  BAD is a proapoptotic member of the 
B-cell leukemia/lymphoma-2 (Bcl-2) family that disrupts the binding of Bcl-2 associated X 
protein (Bax) from Bcl-2. Once Bax is released from Bcl-2 there is a Bax-Bax-oligomerization, 
this Bax-Bax protein complex then inserts into the mitochondrial membrane, causing 
mitochondrial permeabilization (82). When the mitochondrial membrane is permeablized there is 
a release of proapoptotic factors, such as apoptosis inducing factor (AIF) and cytochrome c, 
which begin the apoptotic signaling pathway (10; 42).  When released from the mitochondria, 
cytochrome c and Apaf-1 activate Caspase-9. Active Caspase-9 activates Caspase-3, an apoptotic 
effector that leads to DNA fragmentation and cell death (10; 51). In addition to inhibiting 
apoptosis through BAD phosphorylation, Akt also phosphorylates and inhibits the activity of 
procaspase-9, thus inhibiting the ability of cytochrome c and Apaf-1 to activate this pathway 
(12).  It has also been shown in our lab that recently activated satellite cells are more susceptible 
to apoptosis, and correlates with changes in Bax and Bcl-2 protein levels (69).  Therefore, it 
seems reasonable to conclude that there may be increased apoptosis in myoblast or satellite cells 
in which the anti-apoptotic effect of Akt will diminish, such as that occurring in obesity and 
metabolic syndrome.   
 




Figure 3: Schematic representation of Akt action on apoptotic signaling. 
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OZR as a mode of metabolic syndrome in which to study satellite cell proliferation. 
Skeletal muscles of the obese Zucker rat (OZR), a commonly used animal model of 
metabolic syndrome, are considerably smaller than the skeletal muscles of the control lean 
Zucker rat (LZR) of similar ages (25). The OZR has a homozygous missense mutation of the 
leptin receptor gene resulting in chronic hyperphagia (8) and this causes rapid development of 
obesity, insulin resistance, and hyperlipidemia as early as 6 weeks of age (4; 8; 11; 41).  These 
animals also develop hypertriglyceridemia, hypertention, and the genesis of a prothrombotic and 
proinflammatory state and therefore, the OZR is considered a good model of metabolicsyndrome  
(8; 35). In addition, Akt activity is significantly reduced in the skeletal muscles of the OZR (43), 
and defective Akt signaling is a possible mechanism responsible for the attenuated muscle size. 
Therefore the OZR provides a good model of metabolic syndrome and obesity in which to 
evaluate the potential role of inhibition of satellite cell proliferation resulting in lower muscle 
mass. In this project we examined the proliferation of satellite cells in control muscles of the 
OZR model of metabolic syndrome and determined if satellite cell activation and proliferation 
can be rescued by muscle loading in the OZR. Furthermore, we examined the role of Akt 
signaling in control and loaded muscles of the OZR. 
 
Putative role of palmitate in metabolic syndrome and loss of muscle nuclei. 
Palmitate is the most abundant systemic saturated fatty acid in muscle and is elevated in 
cases of obesity and metabolic syndrome (30; 76) and therefore it has been studied in various 
tissues to better understand the effects of saturated fatty acids in dyslipidemia  (15; 22; 57; 73; 
79). Palmitate treatment has been shown to induce apoptosis in multiple cell types in vitro (21; 
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57; 66; 77). Furthermore, palmitate has been found to inhibit Akt/Protein kinase B (Akt) activity 
in response to insulin (14; 15; 68).  Shorter carbon chained saturated fatty acids, (i.e. laurate), do 
not to interfere with Akt signaling (14; 15); however, their impact on apoptosis has not been 
examined. In this project we have examined the putative role for palmitate to reduce Akt activity, 
leading to apoptosis and loss of nuclei in muscle cells using an in vitro model. 
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Palmitate treatment inhibits C2C12 myoblast proliferation and differentiation 




Myoblast proliferation and differention are highly controlled processes that involve the 
coordination of a variety of cell signaling pathways.  This progression includes cyclins, 
Akt, myogenic regulatory factors, as well as others.  The purpose of this study was to 
determine whether palmitate interfered with myoblast proliferation and or differentiation.  
For these series of experiments C2C12 myoblasts were grown to approximately 60 
percent confluence and then treated with or without 0.25 mM palmitate for 12 hours. The 
effect of palmitate on myoblast proliferation was determined in two separate experiments 
through either pre-staining carboxyfluorescein diacetate, succinimidyl ester (CFSE) or 
with post-treatment incubation with 5-bromo-2-deoxyuridine (BrdU).  Both of these 
techniques revealed that there was a significant decrease in the rate of proliferation in the 
palmitate treated myoblasts.  Furthermore, when the cell cycle was analyzed through 
Propidium Iodide staining there was a significant accumulation of cells in the G2/M 
phase of the cell cycle. Immunoblot analysis of palmitate treated myoblast showed a 
significant decrease in p21, Akt2, myoD, and a significant increase in Foxo3a protein 
expression.  Furthermore, the treatment of myoblasts with palmitate completely abolished 
the formation of myotubes.   The absence of myotube formation corresponded with the 
attenuation of many of the proteins which are normally rapidly expressed at the onset of 
myoblast differentiation, including Akt2, myogenin, and MF20.  These data demonstrate 
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that palmitate treatment not only inhibits the proliferation of myoblast, but palmitate also 
inhibits the formation of new myotubes. 
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INTRODUCTION 
The transition of mono-nucleated myoblast into fully differentiated multi-
nucleated myotubes is a step-by-step process characterized by cell cycle withdrawal, 
expression of muscle-specific proteins, and formation and maturation of myofibers (22). 
A large portion of the control process for these process is regulated by the muscle-
specific helix-loop-helix transcription factors, myoD and myogenin, which are able to 
promote the transcription of muscle specific genes (3, 18, 19).  In addition, to the 
myogenic regulatory factors, forkhead transcriptions factors and cell cycle proteins also 
contribute to the regulation of myoblast differentiation (6, 8).  
Recently, it has been demonstrated that Akt1 and Akt2 play distinct roles in cell 
cycle progression with Akt1 being required for proliferation while Akt2 promotes cell 
cycle exit and is necessary for myoblast differentiation (2, 10, 11).  For, example Akt 
indirectly, through GSK3-β inhibition, increases the activity of cyclin-D (7, 13). Cyclin D 
is a necessary protein for cell cycle progression from the G1 phase of the cell cycle, 
whereas in the absence of cyclin D the cell will be unable to progress through the cell 
cycle (12, 16).  Additionally, Akt signaling can enhance proliferation through the 
forkhead (FoxO) transcription factors.  The FoxO family proteins increase the nuclear 
expression of negative cell cycle proteins, whereas phosphorylation of the FoxO family 
of proteins by Akt negates this effect.  Additionally, the inhibition of the FoxO family of 
proteins results in their nuclear export thus removing the inhibition of the FoxO proteins 
on myogenic regulatory factors (1, 15).  On the other hand, it has been postulated that 
Akt2 may activate MyoD induced myogenin expression, a necessary step for 
differentiation (11).  Combining the aforementioned roles of Akt signaling on the FoxO 
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family proteins as well as the cell cycle proteins it seems reasonable to assume that 
disrupted Akt signaling with metabolic syndrome may not only reduce myoblast/satellite 
cell proliferation, but also reduce myoblast/satellite cell differentiation.  However, the 
effects of metabolic syndrome on muscle cell cycle and differentiation have not been 
studied. 
The purpose of this study was to determine if the addition of the saturated free 
fatty acid (FFA) palmitate inhibits either C2C12 myoblast proliferation and/or 
differentiation.  Palmitate has been previously demonstrated to inhibit Akt activity in 
myotubes but its effects on myoblast proliferation and differentiation are unknown. 
Furthermore, a secondary purpose of this study was to investigate some of the specific 
signaling that is altered with palmitate treatment that may account for the decreases in 
myoblast proliferation and/or differentiation. 
METHODS 
C2C12 Culture. Mouse C2C12 myoblasts were purchased from American Type Culture 
Collection (ATCC).  Cells were cultured in 50 mm polystyrene culture dishes in 
Dulbecco Modified Eagle’s Medium  (DMEM) supplemented with 10% fetal bovine 
serum, and 1% antibiotic antimycotic mixture.  Cells were passaged by trypsinization 
using 0.25% trypsin. Cells were maintained in a humidified incubator under an 
atmosphere of 5% CO2 at 37 ºC. Fresh medium was supplied every 24-36 hours.  
Palmitate (Sigma Chemicals; St. Louis, MO) was administered to cells as 
described by Chavez and Summers (4, 5) with dodecanoic acid (Lauric acid) used as a 
free fatty acid (FFA) control, with an additional control group receiving media only.  
Lauric acid was chosen as a FFA control because it has been shown not to interfere with 
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Akt activity (5).  However, a BSA only group was also used to determine if the FFAs 
affected the measured variables independent of Akt activity. Briefly, palmitate was 
dissolved in ethanol and diluted DMEM containing 2% BSA. C2C12 myotubes were 
incubated with the FFAs (0.25 mM final concentration) in 10% FBS–DMEM in 2% BSA 
for 12 h prior to analysis.  
 
Myoblast proliferation. The first experiment performed was to determine if palmitate 
treatment inhibited myoblast proliferation.  For this experiment C2C12 myoblasts were 
suspended in trypsin, centrifuged at 20ºC for 5 minutes at 1500 rpm and then resuspended 
in PBS. Next 10 µM Carboxyfluorescein Diacetate, Succinimidyl Ester (CFSE) was 
added to the cells and then the staining was immediately quenched with the addition of an 
equal volume of 10% FBS.  An aliquot was fixed in 1% paraformaldehyde, to determine 
initial staining intensity. The cells were then plated into 35mm plates in 10% FBS and 
allowed to grow for 24 hours.  At this point the myoblasts were treated with palmitate, 
Lauric acid, Akt-inhibitor (124005, Calbiochem, Germany) or BSA only and allowed to 
grow for an additional 24 hours.  Next, the myoblasts were washed twice with PBS, 
harvested in 0.25% trypsin, and fixed with 1% paraformaldehyde, and examined using 
the FACSCaliburTM Flow Cytometer. 
An additional proliferation assay was performed in a separated experiment in 
which the C2C12 myoblasts were grown to ~50 percent confluency, pulsed for 20 min 
with 30 µg/ml BrdU (550891, BD Biosciences Pharmingen, USA), harvested in trypsin, 
and fixed in ice cold 70% EOTH for 24 hours.  The myoblast were then resuspended in 
0.1% triton-X/0.1 M HCL for 1 min, centrifuged at 2000 rpm for 5 min, then resuspended  
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in DNA Denaturing Buffer (0.15 µM NaCl, 15 µM Trissodium citrate dihydrate) at 95°C 
for 5 min, followed by incubation at 4ºC for 5 min, and centrifuged 2000 rpm 5 min.  
Next the pellet was washed in 1% BSA in PBS and then resuspended in Mouse anti-BrdU 
(1:50; 555627; BD Pharmingen™, USA) for 30 min at room temperature.  The cells were 
then washed twice in PBS and incubated with Anti-mouse Alexa-488 secondary antibody 
(1:400; A11029; Invitrogen, USA).  Lastly, the myoblasts were wash twice with PBS and 
then resuspended in Propidium Iodide (10 µg/ml; P3566, Invitrogen, USA), RNAse (100 
µg/ml; 10109169001; Roche, USA) in PBS and analyzed using the FACSCaliburTM Flow 
Cytometer. 
 
Flow Cytometry Analysis. The samples were transferred to 5 ml polstytrene round 
bottom tubes for data acquisition and analysis on a FACSCaliburTM Flow Cytometer 
using CellQuest Pro software (BD Biosciences).  All data are represented as mean 
fluorescence intensity (MFI). Additional cell cycle modeling was performed using Modfit 
LT software (Verity Software house, Inc). 
 
Myoblast differentiation. For differentiation into myotubes, the myoblasts were 
grown to 70% confluency and then treated for 12 hours with FFAs (0.25 mM final 
concentration) or BSA only for 12 hours.  After treatment the cells were washed three 
times with DHANKs and then transferred to DMEM containing ITS liquid media 
(Sigma-Aldrich, St. Louis, MO).  All experiments were performed in triplicate. 
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Immunoblot analysis.  The protein contents of the solublized extracts were quantified in 
duplicate by using bicinchoninic acid reagents (Pierce, Rockford, IL, USA) and bovine 
serum albumin (BSA) standards.  60 µg of soluble protein was boiled for 4 min at 100°C 
in Laemmli buffer and loaded on each lane of a 12% polyacrylamide gel.  The proteins 
were separated by routine SDS-PAGE for 1.5 hours at 20°C.  The gels were blotted to 
nitrocellulose membranes (Bio-Rad, Hercules, CA, USA) and stained with Ponceau S red 
(Sigma Chemical Co, St Louis, MO, USA) to confirm equal loading and transferring of 
proteins to the membrane in each lane. 
The membranes were then blocked in 5% non-fat milk in Tris buffered saline with 
0.05% Tween 20 (TBS-T) and probed with appropriate primary antibodies (see table 1).  
Secondary antibodies were conjugated to horseradish peroxidase (HRP) (Chemicon, CA, 
USA) and the signals were developed by chemiluminescence (Pierce, Rockford, IL, 
USA).  The signals were visualized by exposing the membranes to X-ray films (BioMax 
MS-1, Eastman Kodak, Rochester, NY, USA), and digital records of the films were 
captured with a Kodak 290 camera.  The resulting bands were quantified as optical 
density (OD) x band area by a one-dimensional (1-D) image analysis system (Eastman 
Kodak, Rochester, NY, USA) and expressed in arbitrary units.  The sizes of the proteins 
were verified by using standard molecular-weight markers (Bio-Rad, Hercules, CA, 
USA). To reduce the day-to-day variability between blots all comparisons were 
performed on samples run on the same membrane. 
 
Statistical analyses. Statistical analyses were performed using the SPSS 10.0 
software package. A one-way ANOVA was performed on the difference between each 
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variable among treatments.  Statistical significance was accepted at P < 0.05. All data are 




Myoblast proliferation. The first part of this study design was to determine if palmitate 
treatment attenuated myoblast proliferation.  CFSE is a fluorescent dye that stains all the 
protein in the cell.  A subset of the cells was preserved as the parent generation (figure 
1A), each time the myoblast divide the intensity of the stain is reduced by approximately 
one-half.  The myoblast were obtained from one set of parent cells and allowed to grow 
for 24 hours under control treatment.  Our pilot data demonstrated that after 24 hours the 
myoblasts divided approximately three times in the first 24 hours (Data not shown).  
After 24 hours of control treatment the myoblasts were incubated with FFAs, BSA only 
control, or Akt-inhibitor for an additional 24 hours (48 hours total).  The proliferation 
index is an estimation of the number of times the myoblast divided based on the change 
of CFSE fluorescence intensity of the treated myoblasts compared to the parent 
generation (Sample histograms are shown figure 1A and 1B).  This experiment showed 
that both palmitate and the Akt-inhibitor both significantly reduced myoblast 
proliferation (Figure 1C). 
 BrdU is incorporated into proliferating myoblasts as they transition through the S-
phase of the cell cycle.  Figure 2 shows that with both palmitate treatment and Akt 
Inhibitor significantly reduced the incorporation of BrdU into the myoblasts.  Combining 
the CFSE data and the BrdU data it is clear that palmitate treatment significantly reduces 
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myoblast proliferation.  Furthermore, when the cell cycle was analyzed through 
examination of the PI staining it clearly demonstrated that there was a G2 cell cycle shift 
in the palmitate treated myoblasts (figure 3).  This was different then the Akt inhibitor 
treated myoblast which had an increase accumulation in both G1 and G2 cell cycle 
phases.  It has been previously demonstrated that Akt activity is involved with both the 
G1 and G2 cell cycle check points (8, 9, 14), however it is unclear why there is a G2 cell 
cycle shift in the palmitate treated myoblasts. 
 
Akt protein Expression.  To determine the putative impact of Akt signaling in 
accounting for the decrease proliferation in palmitate treated myoblasts the protein 
expression of Akt was determined.  After palmitate treatment there was no change in the 
protein expression of total Akt or Akt1.  However, there was a significant absence of 
Akt2 protein expression in palmitate treated myoblasts (Figure 4A).  It should be noted 
that in C2C12 myoblasts the protein expression of Akt2 is extremely small compared to 
the expression of Akt1 isoform.  In this study the exposure time for Akt1 was 
approximately 30 seconds compared to 5 minutes for Akt2 with all steps besides primary 
antibody being equal.  This would explain why there is no difference observed in either 
total Akt or Akt1 protein expression even though Akt2 protein expression is significantly 
reduced.   
 To determine whether Akt activity was reduced with the palmitate treatment the 
myoblasts were treated as above, and then incubated in serum free media (with or without 
FFAs) for 2 hours before serum was reintroduced to the samples for 10 minutes before 
harvest.  There was a significant reduction in pAkt (Serine 473) protein expression after 
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the reintroduction of serum in the palmitate treated myoblasts (Figure 4B).  This indicates 
that although palmitate did not alter total Akt protein expression it did attenuate the Akt 
activity, as determined through decreased protein expression of pAkt. 
 
Cell cycle regulatory proteins. To further evaluate the mechanism for palmitate induced 
G2 cell cycle phase shift the expression levels of other G2 regulatory proteins were 
investigated. The protein expression of the myogenic regulatory factor MyoD and the 
cyclin-dependent kinase inhibitor p21 were both reduced in the palmitate treatment 
myoblasts.  On the other hand there was an approximately 2-fold increase in the protein 
expression of forkhead transcription factor Foxo3A (figure 5A).  These data are 
consistent with the previous finding of a G2 cell cycle shift and may be part of 
mechanism accounting for the G2 shift.  Other proteins that were examined include p27, 
p53, Foxo1, and Foxo4 however, no differences were observed in the protein expression 
of these proteins with palmitate treatment (data not shown). On the other hand, a small 
decrease in the protein expression of the cell cycle regulatory protein Cyclin B1 with 
palmitate treatment was observed.  However, a band was also observed at ~60 kDa which 
corresponds with a hyper-phosphorylated form of Cyclin B1 in both control treatments, 
but was absent in the palmitate treated myoblasts (figure 5B).  Furthermore, when either 
the BSA or Lauric acid control groups were treated with an Akt inhibitor the 60 kDa band 
of Cyclin B1 was no longer present.   
 
Differentiation.  The last part of this study was to determine whether palmitate treatment 
interfered with the ability for the myoblast to differentiate.  For this series of experiments 
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the myoblasts were treated for 12 hours with or without the FFAs and then washed and 
transferred to differentiation media.  The myoblasts were trypsin harvested at 6, 12, and 
24 hours after being the start of differentiation and stained for Annexin V.  Annexin V is 
an early marker for cells that are undergoing apoptosis, as there is a translocation of the 
membrane phosphatidylserine (PS) from the inner face of the plasma membrane to the 
cell surface, or have become necrotic and the membrane integrity is diminished. 
Although there was no increase in Annexin V positive myoblasts in the palmitate pre-
treated myoblasts after 6 hours in differentiation media, there was an approximately 2-
fold increase in the percent of cells that were Annexin V positive at both 12 and 24 hours 
after the initiation of differentiation. 
 Furthermore, cells were harvested 48 hours after the beginning of differentiation 
and the expression of proteins that are expressed during differentiation were examined.  
The data clearly demonstrates the absence of the proteins that are normally expressed 
during differentiation (figure 6B).  Combined these data demonstrate that the treatment 
on myoblast with palmitate attenuates myotube formation. 
Discussion 
The novel findings of this study are that palmitate treatment significantly reduces 
myoblast proliferation and differentiation.  Furthermore, these data demonstrated that 
with palmitate treatment there is a significant G2 cell cycle shift, indicating that with 
palmitate treatment the myoblasts are unable to pass the G2-check point (17, 21).  
Although palmitate treatment resulted in a reduction in pAkt protein expression and this 
may partially account for the decreased proliferation, and the Akt inhibitor also decreased 
proliferation, the reduction in pAkt protein expression is not sufficient to explain the G2 
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cell cycle shift.  The G2 cell cycle shift may be explained by some of the other proteins 
whose expression levels were alter with the palmitate treatment.  There was a significant 
reduction in protein expression of p21 and MyoD and an increase in the protein 
expression of Foxo3A.  Additionally, there was a significant attenuation of a hyper-
phosphorylated Cyclin B1, with palmitate and with Akt inhibitor. Combined these data 
shed light on a possible mechanism for the G2 cell cycle shift in the palmitate treated 
myotubes (8, 17, 20, 21).   
On the other hand the absence of Akt2 in palmitate treated myoblast most likely 
does not contribute to the attenuated proliferation, but may be a mechanism responsible 
for the attenuation of myoblast differentiation (2, 10, 11).  It has been previously shown 
that when Akt2 is reduced with siRNA treatment in C2C12 myoblast there is complete 
abolishment of myotube formation, whereas Akt1 siRNA transfection had no effect on 
differentiation (2).  It has been proposed that myoD and Akt2 work in conjunction to 
induce the expression of myogenin, a necessary step for myotube formation to occur. 
Combined these data demonstrate that palmitate treatment of C2C12 myoblast 
significantly attenuates proliferation and abolishes myotube formation.  
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FIGURE LEGENDS 
 
Figure 1. CFSE is a fluorescent dye that stains all the protein in the cell.  After initial 
treatment with CFSE dye a subset of the cells was preserved as the parent generation, a 
histogram with the mean fluorescent intensity in a log scale on the x-axes and cell count 
on the why axis is shown (A).   After 24 hours of control treatment the myoblasts were 
incubated with FFAs, BSA only control, or Akt-inhibitor for an additional 24 hours 
before trypsin harvest.  Representative histogram of control myoblasts grown in 10% 
FBS for 48 hours after initial CFSE treatment is shown (B).  Each time the myoblast 
divide the intensity of the stain is reduced by approximately one-half.  The proliferation 
index is an estimation of the number of times the myoblast divided based on the change 
of CFSE fluorescence intensity of the treated myoblasts compared to the parent 
generation (C).  This experiment showed that both palmitate and 10 µM Akt-inhibitor 
both significantly reduced myoblast proliferation.  The data are displayed as mean ± SE.  
*p < 0.05 vs. control samples.  Abbreviation: Con = BSA only control; Laur = Lauric 
acid free fatty acid control; Pal = Palmitic acid treated AktI = Treated with 10 µM Akt 
Inhibitor; CFSE = Carboxyfluorescein Diacetate, Succinimidyl Ester. 
 
Figure 2.  BrdU is incorporated into proliferating myoblasts as they transition through 
the S-phase of the cell cycle.  Figure 2A shows a representative graph displaying Flow 
Cytometry data with the mean fluorescent intensity (MFI) of BrdU-alexa 488 on the y-
axis and MFI of propidium Iodide on the x-axis.  Figure 2B displays the number of cells 
for each treatment that are BrdU positive. The data are displayed as mean ± SE.  *p < 
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0.05 vs. control samples.  Abbreviations: Con = BSA only control; Laur = Lauric acid 
free fatty acid control; Pal = Palmitic acid treated; AktI = Treated with 10 µM Akt 
Inhibitor; BrdU = Bromodeoxyuridine (5-bromo-2-deoxyuridine). 
 
Figure 3. Cell cycle was analyzed through examination of the PI staining.  A) 
Representative histogram is demonstrated cell number in is each phase of the cell cycle 
based on the staining intensity of Propidium Iodide.  B)  Palmitate and AktI treated 
myoblasts had significantly decreased number of myoblasts in the S-phase of cell cycle.  
Palmitate treatment resulted in a significant accumulation of myoblasts in the G2/M 
phase of the cell cycle. The data are displayed as mean ± SE.  *p < 0.05 vs. control 
samples.  Abbreviations: Con = BSA only control; Laur = Lauric acid free fatty acid 
control; Pal = Palmitic acid treated; AktI = Treated with 10 µM Akt Inhibitor. 
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ABSTRACT 
The obese Zucker rat (OZR) is a model of the metabolic syndrome, which has lower skeletal 
muscle size compared to the lean Zucker rat (LZR).   Because satellite cells are essential for 
postnatal muscle growth, this study was designed to determine if reduced satellite cell 
proliferation contributes to the reduction of skeletal mass in the OZR compared with the LZR.  
Satellite cell proliferation was determined by a constant release 5-bromo-2-deoxyuridine (BrdU) 
pellet that was placed subcutaneously in each animal. Satellite cell proliferation, as determined 
by incorporation of BrdU, was significantly attenuated in control soleus and plantaris muscles of 
the OZR compared to the LZR.  To determine whether this attenuation of satellite cell activity 
could be rescued in OZR muscles, the soleus and the gastrocnemius muscles were denervated, 
placing a compensatory load on the plantaris muscle. There was a ~25% and ~30% increase in 
the plantaris muscle wet weight compared to the contra-lateral control muscle  in the LZR and 
the OZR, respectively after 21-days of loading.  The number of BrdU positive nuclei increased 
similarly in loaded plantaris muscles from LZR and OZR.  Myogenin, MyoD and Akt protein 
expression, were lower in the control muscles of OZR compared to LZR, but they were all 
elevated to similar levels in the loaded plantaris muscles of OZR and LZR.  These data indicate 
that metabolic syndrome may reduce satellite cell proliferation and this may be a factor that 
contributes to the reduced mass in control muscles of OZR; however, satellite cell proliferation 
can be restored with compensatory loading in OZR. 
 
 
Key Words: muscle stem cells, muscle hypertrophy, metabolic syndrome, myogenic 
transcription factors
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Introduction 
The obese Zucker rat (OZR) is a widely accepted model of the metabolic syndrome,  which 
occurs as a result of a homozygous missense mutation of the leptin receptor gene (9) leading to 
chronic hyperphagia (9,21). As a result, the OZR  rapidly becomes obese and develops extreme 
insulin resistance and hypertriglyceridemia, which is accompanied by a clinically relevant 
hypertension and a prothrombotic and proinflammatory state (5,16,20,22,28,36). Skeletal 
muscles are considerably smaller in the OZR than in the control lean Zucker rat (LZR) of similar 
ages.  This is important because skeletal muscle, is the primary site of glucose and fat oxidation, 
both of which are in excess with metabolic syndrome (6,27). Therefore, a reduction of skeletal 
muscle mass would further compromise clinical outcomes in metabolic syndrome.  
The lower skeletal muscle mass in the OZR appears to be partly accounted for by an altered 
balance between protein synthesis and degradation in this model of metabolic syndrome (4,16). 
However, it has also been observed that there is a decrease in nucleic acid content in the muscles 
of the OZR compared to the LZR (16). Replacing nuclei that are lost during normal turnover and 
maintaining nuclear content in adult muscle, is a primary responsibility of muscle satellite cells.  
Muscle satellite cells are normally quiescent myogenic precursor cells found between the basal 
lamina and the sarcolemma of a muscle fiber (1).  However, these cells can proliferate in 
response to a variety of stimuli, and they are responsible for maintenance of the nuclear to 
cytoplasmic relationship in muscle. Furthermore,  postnatal muscle growth and hypertrophy of 
skeletal muscle, critically depend on the proliferation and differentiation of muscle satellite cells 
(1,25). It is possible that a decrease in satellite cell proliferation could contribute to the decrease 
in nucleic acid content and skeletal muscle mass observed in the OZR.      
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Mechanisms that may contribute to lower satellite cell proliferation and differentiation in 
muscles of the OZR could include decreases in the expression levels of myogenic regulatory 
factor proteins. Myogenic regulatory factors are muscle-specific helix-loop-helix transcription 
factors which regulate muscle specific genes (12,25).  MyoD and myogenin are myogenic 
regulatory factors which are expressed in activated satellite cells and they are necessary for 
satellite cell proliferation and differentiation  (12,37).  MyoD and myogenin are reduced during 
muscle atrophy, and in models of diabetes (3,13), although it has not been determined if this 
corresponds to reduced satellite cell proliferation or differentiation in models of the metabolic 
syndrome. We hypothesized that a decrease in the protein expression of MyoD and myogenin 
might result in lower satellite cell proliferation and/or differentiation and lead to lower muscle 
mass in the OZR model of metabolic syndrome, as compared to the lean phenotype. 
Another possible mechanism for disrupted satellite cell proliferation is deregulated protein 
kinase B/Akt (Akt) signaling.  Control of the Akt signaling pathway is essential for muscle 
growth and hypertrophy (reviewed (7,19)).  Furthermore, a lower level of activated Akt is 
associated with attenuated increases in muscle hypertrophy under conditions such as aging 
(7,19). Akt, and specifically Akt2, is essential for proliferation and differentiation of skeletal 
muscle satellite cells (7,8).  In the OZR there is a reduced protein expression of Akt2 and 
reduced activity levels of both Akt1 and Akt2 compared to the LZR (24). These findings 
underscore the possibility that Akt signaling may play an important role in the control of satellite 
cell proliferation and differentiation in muscles of the OZR. 
Although the skeletal muscles of the OZR are smaller compared to the LZR, to the best of 
our knowledge, no study has evaluated whether muscles in the OZR have attenuated hypertrophy 
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in response to loading.  While the OZR is significantly less active than the LZR (9), the OZR 
have much greater body mass, and this should provide a greater stimulus for muscle growth on 
the weight bearing muscles.  Nevertheless, a previous study from our lab in which the daily 
activity of the OZR was increased through daily treadmill running, demonstrated no increase in 
the size of the skeletal muscles (18).  These findings suggest that there may be an underlying 
deficit in the ability of skeletal muscle to respond to increased loading in the OZR model of 
metabolic syndrome. 
The purposes of this study were to determine (i) if there was a decrease in the number of 
satellite cells in the skeletal muscles of the OZR compared to the LZR (ii) whether satellite cell 
proliferation is attenuated in OZR compared to the LZR in control muscle; (iii) whether satellite 
cell proliferation is attenuated in OZR compared to the LZR in loaded muscle; and, (iv) whether 
the skeletal muscles of the OZR are able to hypertrophy in response to loading.  Furthermore, as 
muscle loading directly activates Akt (31) and MRF signaling (2,26), Akt, MyoD, and myogenin 
protein expression were measured. We hypothesized that Akt and MRF protein expression would 
be rescued with compensatory hypertrophy in the OZR, and enable a restoration of satellite cell 
proliferation to levels similar to lean animals.  
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METHODS 
Animal Care. Male LZR (+/fa) and OZR (fa/fa) rats were purchased from Harlan labs 
(Harlan, Indianapolis, IN).  The OZR are homozygous for a recessive missense mutation of the 
leptin receptor gene which results chronic hyperphagia. The LZR are heterozygous for this 
mutation but do not shown eating abnormalities (9,29). Twelve animals of each phenotype were 
used in this study. All animals were 12 weeks of age at completion of this study. The animals 
were housed in pathogen-free conditions, at 20-22°C, and fed rat chow and water ad libitum 
throughout the study period. The animal care standards were followed by adhering to the 
recommendations for the care of laboratory animals, as advocated by the American Association 
for Accreditation of Laboratory Animal Care, which fully conformed to the Animal Welfare Act 
of the US Department of Health and Human Services. All animal procedures were conducted in 
accordance with institutional guidelines and ethical approval was obtained from the Animal Care 
and Use Committee at the West Virginia University prior to carrying out tests. 
Compensatory loading protocol. To achieve compensatory hypertrophy of the plantaris 
muscle, synergist denervation of the soleus and gastrocnemius muscles was used as previously 
described in our (14). Briefly, the distal branches of the tibial nerve were transected, therefore, 
removing the innervation to the soleus muscle and both heads of the gastrocnemius muscle.  The 
severed nerved endings were sutured onto the biceps femoris muscle to prevent reinnervation 
back to the original muscles (14).  This placed a compensatory load on the plantaris muscle. The 
contralateral limb received a sham surgery, in which the branches of the tibial nerve were 
identified but not severed, and this served as an internal control for each animal.  All procedures 
were performed under aseptic conditions. The animals recovered quickly and were alert and 
walking within ~15 min after surgery. Loading occurred for 7 or 21 days. 
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Bromodeoxyuridine (BrdU) implantation. A time-released 5-bromo-2-deoxyuridine (BrdU) 
pellet (21-day release, 0.22 µg BrdU·g body mass–1·day–1; Innovative Research, Sarasota, FL) 
was placed subcutaneously on the dorsum of the back of each animal. BrdU is a thymidine 
analog and is incorporated in nuclei during DNA synthesis. Skeletal muscle nuclei are post-
mitotic and cannot incorporate BrdU into their DNA. In contrast, satellite cells can incorporate 
BrdU during proliferation. Therefore,  BrdU positive nuclei located under the basal lamina  can 
be identified as satellite cells that have proliferated, migrated and  become incorporated into a 
muscle fiber (1). Therefore, BrdU was used to identify satellite cells/muscle precursor cells that 
had proliferated during the 7- or 21-day period of muscle loading-induced hypertrophy. Only the 
BrdU positive nuclei within the basal lamina were quantified. The BrdU labeling index was 
calculated as the number of BrdU labeled myonuclei .  total myonuclei-1 . 100. This provided an 
index of satellite cell proliferation. 
Tissue Collection.  The plantaris muscles were collected 7 days (n=6 LZR-7 and n=6 
OZR-7) or 21 days (n=6 LZR-21 and n=6 OZR-21) after the surgical denervation of the 
synergists. The animals were 12 weeks old at time of tissue collection. The rats were 
anaesthetized with ketamine hydrochloride, (9 mg x 100 g body weight–1) and xylazine 
hydrochloride (1 mg x 100 g body weight–1), I.P. and the plantaris muscles from each limb were 
removed and frozen in  isopentane, cooled to the temperature of liquid nitrogen, and stored at -
80°C until further analysis.  Additionally, a mid-belly section of each muscle was fixed in 10% 
formalin and was embedded in paraffin. 
Immunoblot protein analysis. Total protein homogenates were prepared in lysis buffer 
(20 mM Tris pH 7.5, 150 mM NaCl, 1% Nonidet P-40, 0.5% Sodium Deoxycholate, 1 mM 
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EDTA, 0.1% SDS) with the addition of a protease inhibitor (Sigma Chemical Co, St Louis, MO, 
USA). The protein contents of muscle homogenates were quantified in duplicate by using 
bicinchoninic acid reagents (Pierce, Rockford, IL, USA) and bovine serum albumin (BSA) 
standards. The mitochondria-free cytosolic protein fraction was isolated as previously described 
(33)  and used for immunoblotting for apoptosis inducing factor (AIF). AIF was used as an index 
of mitochondria permeability and release of pro-apoptotic factors to the cytosolic protein 
fraction. 50 µg of soluble protein was boiled for 4 min at 100°C in Laemmli buffer and separated 
on a 4-12% gradient polyacrylamide gel (Invitrogen, USA).  The gels were blotted to 
nitrocellulose membranes (Bio-Rad, Hercules, CA, USA) and stained with Ponceau red (Sigma 
Chemical Co, St Louis, MO, USA) to confirm equal loading and transfer of proteins to the 
membrane. 
 The membranes were then blocked in 5% non-fat milk in Tris buffered saline containing 
0.05% Tween 20 (TBS-T) and probed with antibodies to Akt, Akt1, Akt2 (Cell Signaling 
Technology, MA, USA), MyoD or myogenin (Santa Cruz, CA, USA). To determine if apoptotic 
signaling was enhanced in control muscles of OZR animals, the membranes were probed with 
antibodies to: AIF, apoptotic protease activating factor 1 (Apaf-1), apoptosis repressor with a 
caspase recruitment domain (ARC), and Bcl-xL/Bcl-2 associated death promoter (BAD), (Santa 
Cruz, CA, USA).  As a further confirmation of equal loading and blotting of the proteins, the 
membranes were also probed for ß-tubulin or GapDH (Abcam, MA, USA). Secondary antibodies 
were conjugated to horseradish peroxidase (Chemicon, CA, USA) and the signals were 
developed by chemiluminescence (ECL advance, Amersham Biosciences).   The signals were 
visualized by exposing the membranes to X-ray films (BioMax MS-1, Eastman Kodak, 
Rochester, NY, USA), and digital records of the films were captured with a Kodak 290 camera.  
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The resulting bands were quantified as optical density (OD) x band area by a one-dimensional 
(1-D) image analysis system (Eastman Kodak, Rochester, NY, USA) and expressed in arbitrary 
units normalized to ß-tubulin or glyceraldehyde 3-phosphate dehydrogenase (GapDH; Abcam 
Inc. Cambridge, MA). 
 
Immunofluorescent staining. Paraffin embedded, 7-µm-thick, muscle-cross sections from  
loaded and control plantaris muscles were de-paraffinized in xylene, followed by rehydration in 
graded ethanol washes, and then rinsed in distilled water.  The tissues sections were incubated in 
an antigen retrieval buffer (10mM sodium citrate, 0.05% Tween-20, pH 6.0) for 30 minutes at 
95ºC, washed in phosphate buffered saline (PBS) and then blocked in 1.5% goat serum in PBS at 
37ºC for 30 min. Sections were then incubated with an anti-BrdU mouse monoclonal antibody 
(BD Pharmingen, San Diego, CA) followed by an anti-mouse Alexa 488 (Invitrogen, CA). 
Negative control experiments were done by omitting the BrdU antibody from the tissue sections. 
The basal lamina was identified with a primary antibody to anti-laminin (D18; Hybridoma Bank) 
followed by a rhodamine conjugated secondary antibody (Santa Cruz Biotechnology, CA). Only 
the BrdU positive nuclei within the basal lamina were quantified. The BrdU labeling index was 
calculated as the number of BrdU labeled nuclei. total nuclei -1 . 100. This provided an index of 
satellite cell proliferation. 
Pax7 antibody (PAX7; Developmental Studies, Hybridoma Bank, U. Iowa) was used to 
determine the number of satellite cells in the control muscles (40). Since the formalin fixation 
interfered with the Pax7 antibody, 7µm cross-sections were obtained from frozen mid-belly 
sections of the muscle as previously performed in our laboratory (34). Briefly, the sections were 
air dried at room temperature, fixed in ice-cold methanol-acetone (1:1) for 10 minutes, rinsed in 
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PBS, and permeabilized in 0.2% triton-X in 0.1% sodium citrate. The sections were incubated 
for 30 minutes in 1.5% goat serum at 37ºC then incubated with a primary antibody to Pax7 
followed by  Alexa 488. The tissue sections were then probed with anti-Laminin mouse IgG2a 
(2E8; Hybridoma Bank) followed by a rhodamine conjugated secondary antibody (Santa Cruz 
Biotechnology, CA). 
Immunoblot analysis was completed on 6 non-overlapping tissue cross-sections (40x 
magnification). Three cross- sections were examined in each muscle.  Myonuclei were only 
counted for analysis if they resided within the basal lamina. Pax7 positive nuclei were identified 
as quiescent satellite cells, because neither myonuclei nor activated/differentiated satellite cells 
express Pax7 (40).  Additionally, skeletal muscle nuclei are post-mitotic, and therefore any 
nuclei residing under the basal lamina that were BrdU positive were identified as proliferated 
satellite cells (1). The BrdU labeling index was calculated as the number of BrdU labeled 
myonuclei .  total myonuclei-1  .  100 and this was used as an index of satellite cell proliferation.   
 
In situ TdT-mediated dUTP nick end labeling (TUNEL) staining.  Apoptotic nuclei were 
assessed from muscle cross-sections via a TUNEL assay.  10-μm-thick frozen sections were cut 
in a freezing cryostat at -20°C from plantaris muscle cross-sections. Apoptotic nuclei were 
identified by a fluorometric TUNEL detection kit (Roche Applied Science, Indianapolis, IN) 
according to the manufacturer’s instructions for both C2C12 myoblasts and muscle cross 
sections. Briefly, tissue sections were fixed in 4% paraformaldehyde in PBS, pH 7.4, at room 
temperature for 20 min, permeabilized with 0.2% Triton X-100 in 0.1% sodium citrate at 4°C for 
2 min, and incubated with fluorescein-conjugated TUNEL reaction. Negative control 
experiments were done by omitting the TdT enzyme in the TUNEL reaction mixture on the 
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tissue sections. After TUNEL labeling, the muscle sections were incubated with an anti-laminin 
monoclonal antibody (2E8; Hybridoma Bank, Iowa) followed by an anti-mouse (Cy3 Conjugate, 
C2181) and mounted with 4',6-Diamidino-2-phenylindole (DAPI; Vectashield® mounting 
medium).  TUNEL- and DAPI-positive nuclei and laminin staining were examined under a 
fluorescence microscope, and the captured images were stacked using a SPOT RT camera 
(Diagnostic Instruments, Sterling Heights, MI), and SPOT RT software (Universal Imaging, 
Downingtown, PA). The number of TUNEL and DAPI-positive nuclei was counted from six 
random, non-overlapping fields at an objective magnification of x40. Only the labeled nuclei that 
were under the laminin staining were counted, to exclude any non-muscle nuclei in the sections. 
Data were expressed as number of TUNEL-positive nuclei per 100 nuclei counted.   
 
Statistical analyses. Statistical analyses were performed using the SYSTAT 11.0 software 
package. A one way Analysis of variance (ANOVA) was performed on the difference in all 
measured variables. The effect of loading on muscle wet-weight was determined by comparing 
muscle wet-weights from control and loaded limbs with a paired T-test.  The percent change in 
muscle wet weight was calculated for each individual animal and the means from these data for 
each animal group (n=6/group) are presented in Figure 1.  Satellite cell proliferation index, body 
weight, control or loaded soleus muscle weight, control or loaded plantaris muscle weight, Pax7 
positive nuclei, BrdU positive nuclei, protein expression levels, and nuclei number per muscle 
fiber were analyzed using a 2 way ANOVA (phenotype x treatment; control or loaded).The 
satellite cell proliferation index, and protein expression were not compared between 7 days post 
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surgery and 21 days post surgery. Statistical significance was accepted at P < 0.05. All data are 
presented as means + standard error. 
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RESULTS 
 Muscle characteristics. The OZR had significantly more body weight than the LZR.  The 
control plantaris and soleus muscles of the OZR were significantly smaller than the LZR after 7- 
or 21 days of compensatory loading. 7-days of loading did not significantly increase muscle wet 
weight in either LZR or OZR. However, 21 days of loading increased the mass of the plantaris 
muscles by 23 + 12.8% in the LZR-21 and 32 + 13% in the OZR-21 (Figure 1).  These data 
indicate that the compensatory loading protocol used in this study was sufficient to induce 
hypertrophy in both the obese and lean phenotype over a 21-day time point. 
Quiescent satellite cells. Pax 7 was used as a marker to identify quiescent satellite cells 
(40) in tissue cross-sections from soleus and plantaris muscles.  The number of quiescent satellite 
cells was expressed as a percentage of total myonuclei (DAPI-positive nuclei within the muscle 
fiber, as determined by staining of the basal lamina). The percentage of Pax7 positive nuclei to 
total myonuclei was similar in plantaris and soleus muscles of OZR and LZR animals (Figure 
2A). However, there were fewer total myonuclei in muscles of OZR animals compared to LZR 
animals. There was a significant, ~30% and 20% decrease, in the number of myonuclei per 
muscle fiber cross section in plantaris and soleus muscles respectively, of OZR compared to the 
LZR (Figure 2B). Together these data signify that although the percentage of satellite cells (as 
indicated by Pax7) to total myonuclei is not reduced, there are less total myonuclei in the OZR. 
This suggests that there was not a preferential loss of satellite cells in the muscles of the OZR, 
but rather, there was a proportional decrease in the number of satellite cells and myonuclei in 
muscles of OZR compared to LZR. 
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Apoptotic signaling proteins. We examined if increased nuclear apoptosis may account 
for the fewer nuclei found in muscles fibers of the OZR compared with the LZR.  Surprisingly, 
immunoblot analysis showed similar levels of AIF, ARC, APAF-1, and Bad protein content in 
control muscles of OZR and LZR (Figure 3). Similarly, apoptotic nuclei as reflected by the 
frequency of TUNEL positive nuclei were less than 1% of the total myonuclei and there was no 
difference in the number of apoptotic nuclei in the muscle cross-sections from LZR and OZR 
animals. These data suggest that apoptosis is not increased and therefore cannot account for the 
fewer number of myonuclei and satellite cells in muscles of the OZR compared with the LZR. 
 
Satellite cell proliferation. One possible explanation for the lower number of myonuclei 
is that satellite cell proliferation and replacement of nuclei could be impaired in control muscles. 
To test this possibility, we examined satellite cell proliferation in the muscles of the OZR 
compared to the LZR, in control muscles. To determine if satellite cell proliferation could be 
rescued to contribute to muscle hypertrophy, we examined loaded plantaris muscles. BrdU time 
release pellets were implanted in all animals to label proliferated satellite cells. In the 
contralateral control limb there was a significant absence of BrdU positive nuclei in the OZR 
compared to the LZR in both the plantaris (Figure 4D) and soleus muscles (Figure 4E).  In this 
study, only one BrdU positive myonuclei was observed in all the control plantaris muscle cross 
sections that were examined from OZR, and only two BrdU positive myonuclei were observed in 
all of the control OZR soleus muscles. In contrast, every cross section that was examined in the 
LZR had a minimum of one BrdU positive nuclei. These data support the hypothesis that there is 
a decrease in satellite cell proliferation in the control muscles of the OZR compared to the LZR. 
On the other hand, loading of the plantaris muscle induced a significant increase in the number 
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of BrdU positive muscle nuclei in both the OZR and LZR (Figure 4D).  The number of BrdU 
positive nuclei was similar in loaded muscles from OZR animals. 
Myogenic regulatory factors and Akt protein expression. As expected, immunoblot 
analysis demonstrated that there was a significant decrease in both MyoD and myogenin protein 
levels in the control plantaris muscles of the OZR compared to the LZR (Figure 5).  After 7-days 
of loading there was a similar ~2 and ~3-fold increase in the relative protein level of myogenin 
and MyoD, respectively, in both the LZR and OZR.  After 21-days of loading, there was no 
longer a difference in the protein expression of MyoD and myogenin in the loaded plantaris 
muscles of LZR compared to the control limbs.  However, MyoD and myogenin protein levels 
remained elevated in the plantaris muscles from OZR after 21-days of loading compared to the 
contralateral control (Figure 5).  
There was a decrease in total Akt protein expression as well as the relative Akt2 isoform 
content, with no changes in Akt1 content in the control muscles of the OZR compare to the LZR. 
Compensatory loading increased the protein expression of both Akt1 and Akt2 protein content in 
plantaris muscles of the LZR and the OZR (Figure 6).  After 21-days of loading, there was no 
difference in total Akt, Akt1, or Akt2 protein expression in the loaded plantaris muscle of the 
OZR compared to the LZR.  These data indicated that although the protein expression levels of 
myogenic regulatory factors and Akt are reduced in control muscles in the OZR model of 
metabolic syndrome, they can be restored with a sufficient stimulus such that induced during 
compensatory loading. 
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DISCUSSION 
This study demonstrated a number of novel findings regarding satellite cell proliferation 
in the skeletal muscles of the OZR model of metabolic syndrome.  First, there was a decrease in 
the number of myonuclei in muscle fiber cross-sections of the OZR compared with the LZR.  
Second, this study is the first to show that hypertrophy is not impaired in muscles of the OZR 
model of metabolic syndrome, if the stimulus is adequate. In addition, to the best of our 
knowledge, this is the first study to observe any form of loading-induced hypertrophy in any 
rodent model of metabolic syndrome.  The third novel finding is that although there is no change 
in the proportion of quiescent satellite cells in control muscles, there was a significant 
attenuation of satellite cell proliferation of adult muscle under normal control  loading conditions 
in the OZR compared with the LZR.  The attenuation of satellite cell proliferation in control 
soleus and plantaris muscles that we observed in this study, may result in a decreased 
replacement of myonuclei during normal nuclear turnover. This could account for the decreased 
nucleic acid content in the skeletal muscles of the OZR compared to LZR observed by Durschlag 
and colleagues (16), as well as the decreased number of myonuclei in muscle fiber cross-sections 
in the OZR compared to the LZR. It has been previously shown that both Akt protein expression 
and activity levels are decreased in control muscles of the OZR when compared with the LZR 
(24). Because Akt signaling is a major component contributing to skeletal muscle hypertrophy 
(7,11), it was anticipated that the lower Akt protein levels in  plantaris muscles of the OZR 
would result in attenuated hypertrophy in response to compensatory loading compared to the 
LZR.  However, no attenuation of satellite cell proliferation or muscle hypertrophy was found in 
the OZR after compensatory loading of the plantaris muscle.   
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Muscle hypertrophy in response to normal growth or muscle loading in adults is critically 
dependent on the proliferation and differentiation of satellite cells (30). Reduction in muscle 
DNA content (10) as a result of reduced muscle nuclei content (35) is one mechanism 
contributing to lower muscle transcriptional activity and muscle mass with aging, and potentially 
leading to sarcopenia in aging. Thus, it is possible that in a similar fashion, reduced proliferation 
of satellite cells will contribute to lower nuclear content in skeletal muscle of OZR, which may 
have contributed to reduced muscle mass in control muscles compared with LZR. In this study, 
satellite cell proliferation was determined by identifying nuclei inside the basal lamina that had 
incorporated BrdU during compensatory hypertrophy of the plantaris muscle of OZR and LZR. 
We would not expect to see a high number of satellite cells being activated in adult skeletal 
muscle in humans under normal basal conditions. However, unlike humans, rodents, continue to 
grow throughout their life cycle so one would expect to see a small amount of satellite cell 
proliferation even in adult rodent muscles.  This expectation was confirmed in our finding of 
BrdU positive myonuclei in the LZR control soleus and plantaris muscles. The initial hypothesis 
proposed for this study was that satellite cell proliferation would be inhibited in the OZR model 
of metabolic syndrome, regardless of loading. This hypothesis was partial confirmed by the 
almost complete absence of BrdU positive myonuclei in the control plantaris and soleus muscles 
of the OZR.   On the other hand, after loading, the number of BrdU positive myonuclei was 
elevated in the LZR, but surprisingly there was an almost equal amount of BrdU positive nuclei 
in the loaded plantaris muscle of the OZR and the LZR.  We did anticipate that if satellite cell 
proliferation was restored it would coincide with a restoration of Akt and myogenic regulatory 
factor protein expression as we observed in this study.  Previous studies from our lab and others 
have shown that loading-induced hypertrophy is accompanied by increases in MyoD and 
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myogenin (2,10), whereas,   muscle wasting and aging are usually accompanied by decreases or 
attenuated increases in protein levels of myogenic transcription factors (2,15,26). In old birds, 
the lower levels of myogenic regulatory factors appear to result from reduced contributions from 
satellite cells (25); however, restoration of myogenic regulatory factor levels from muscle 
loading could reflect changes in both myonuclei and satellite cells (25). In the present study, it is 
likely that the increased load on the plantaris muscle was sufficient to increase the activation of 
Akt in a contraction dependent manner (32) and that the increase in Akt induced increased 
expression of myogenic regulatory factors (23).   
Traditional treatments for metabolic syndrome, as recommended by the American 
Diabetes Association, include weight loss and aerobic exercise.  Aerobic exercise increases 
whole-body glucose disposal and improves insulin sensitivity, mainly through increased 
expression of GLUT-4 protein (17). However, aerobic exercise is not considered an effective 
means to induce skeletal muscle hypertrophy.   On the other hand, resistance exercise has also 
been shown to  increase glucose transport into the muscle (38) and is widely accepted as a means 
to induce muscle hypertrophy.   
 To the best of our knowledge, this is the first study to demonstrate hypertrophy in an 
animal model of metabolic syndrome.  It is important to note that metabolic syndrome did not 
limit muscle hypertrophic adaptations to increased loading. Another important finding of this 
study is that there was a restoration of Akt2 protein expression in hypertrophied muscles of OZR 
after overload.  Akt2 specifically has been linked to disruptions in GLUT4 regulation, glucose 
uptake, as well as skeletal muscle hypertrophy (8,11,31).  Skeletal muscle, by virtue of its mass, 
is the primary site for glucose and fatty acid oxidation, both of which are important 
complications with metabolic syndrome (6,27).  These findings suggest that resistance training, 
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or some other form of loading, may be a viable addition to the treatment and/or prevention of 
metabolic syndrome in humans.  
To our knowledge, this is the first study in which satellite cell quantification and 
proliferation with metabolic syndrome has been investigated. We do not think that increased 
apoptotic signaling could account for the lower number of myonuclei and satellite cells in cross-
sections of control muscles of the OZR, because we have failed to observe any increases in 
markers of apoptosis (TUNEL positive nuclei; protein levels of AIF, Apaf-1, ARC or BAD) in 
control muscles of the OZR compared with the LZR. Furthermore, it is unlikely that metabolic 
syndrome attenuates the sustained increases in ribosomes, thereby limiting translational capacity, 
as is the case in some chronic diseases (1), because in the present study, the plantaris muscles 
had similar hypertrophic adaptations to compensatory loading in OZR and LZR. We speculate 
that lower Akt and MyoD levels in control muscles of OZR might in turn result in decreased 
satellite cell proliferation. This hypothesis is supported by recent data that show that leptin 
promotes proliferation and inhibits myogenin expression and myoblast differentiation in vitro 
(39), and therefore the lack of leptin might result in an inhibition of satellite cell proliferation. In 
the current study, there was a significant decrease in the protein expression of myogenic 
regulatory factors, myogenin and MyoD, as well as Akt, which could account for the decreased 
satellite cell proliferation in the control muscles of the OZR. It is not clear if the lower levels of 
MyoD and Akt are leptin dependent or independent, or simply a response to or a consequence of 
metabolic syndrome.  Thus, it is possible that deficient leptin signaling or some other aspect of 
metabolic syndrome attenuates the expression of these proteins. To test this further, other models 
of obesity and metabolic syndrome would need to be investigated in which leptin levels were 
manipulated.  Nevertheless, in the current study, MyoD, myogenin, and Akt protein expression 
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were restored with loading, indicating that a significant stimulus, such as compensatory loading, 
is capable of overriding the attenuation of these proteins.  Our results show that overload-
induced muscle hypertrophy and satellite cell proliferation occurs at similar levels in skeletal 
muscles of OZR and LZR, suggesting that satellite cell function per se is not limited in metabolic 
syndrome.   
In conclusion, our data suggest that satellite cell proliferation is suppressed in control 
muscles of OZR with metabolic syndrome. This may lead to an impaired replacement of nuclei 
during normal turnover, and in turn, may contribute to the reduced number of myonuclei per 
muscle and the lower muscle mass in animals with metabolic syndrome. These findings 
underscore the need for further research to more fully understand the mechanisms responsible for 
attenuated satellite cell proliferation in control muscles in the OZR and to determine if satellite 
cell activity or proliferation is reduced in other models of the metabolic syndrome.  
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Table 1 Animal characteristics. 
 LZR  OZR  
Body weight (g)  296 + 17  497 + 78*  
Plantaris control (mg)  272 + 14  220 + 18* 
Soleus control (mg) 167 + 20  144 + 9*  
Glucose (mg/dl) 100.7 + 49 193.2 + 44 
 
LZR, lean Zucker rats; OZR, obese Zucker rats.  *=significant vs. LZR Data reported as mean + 
SE. 
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FIGURE LEGENDS 
Figure 1.  A compensatory load was placed on the plantaris muscle by denervating the soleus 
and gastrocnemius muscles. The contra-lateral control muscle received a sham surgery.  The data 
shown are the percent change in the muscle wet-weight in the loaded plantaris, with 7- or 21- 
days of loading, compared to the contralateral control.  The effect of loading on muscle wet-
weight was determined by comparing muscle wet-weights from control and loaded limbs.  The 
percent change in muscle wet weight was calculated for each individual animal and the means 
from these data are presented for each animal group (n=6/group).  After 7-days of loading the 
percent change in muscle weight was not significant in either the LZR or OZR, however at 21-
days of loading the percent change in both phenotypes was significant. Data presented as mean + 
SE. *, p <0.05 vs. contralateral control.  Abbreviations: LZR, Lean Zucker rat; OZR, Obese 
Zucker rat; -7, 7 days of loading; -21, 21 days of loading.  
 
Figure 2.  Quiescent satellite cells were labeled with a Pax7 antibody and reported as a percent 
of the total myonuclei in the control plantaris and soleus muscles. Myonuclei were identified 
with DAPI and quantified if they were located within the basal lamina. Representative images of 
muscle cross-sections are shown with antibody labeling to Pax7 only (A); Pax7 plus the DAPI 
nuclear stain (B); and Pax7, DAPI, and Laminin antibody labeling (C).  Each Pax7 positive 
nuclei was counted in 6 non-over-lapping microscopic fields. The data were normalized to the 
total number of nuclei in the same number of fields to obtain the percent of Pax7 nuclei as a 
percentage of total myonuclei. There was no difference in the proportion of Pax7 positive nuclei 
to total myonuclei between the LZR and OZR in either the plantaris or soleus muscles (D).  In 
addition, the numbers of myonuclei for each muscle-fiber cross section were also examined.  
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There were a significantly lower amount of nuclei in cross-sections of muscle fibers in the OZR 
compared to the LZR in both soleus and plantaris muscles (E). Data presented as means + SE. *, 
p < 0.05 OZR (n=12) vs. LZR (n=12). Abbreviations: LZR, Lean Zucker rat; OZR, obese Zucker 
rat.  
 
Figure 3.  Representative immunoblots of apoptotic signaling proteins in control plantaris 
muscles from the lean Zucker rat (LZR) and the obese Zucker rat (OZR). There were no 
differences between the content of these proteins in muscles of OZR and LZR (quantification  of 
blot data are not shown) . 
 
Figure 4. A representative immunofluorescent image (green) of BrdU stained with Alexa-488 
(A), BrdU labeling as in A coupled with and a DAPI (blue) nuclear stain (B), and incubated with 
a (red) rhodamine conjugated  anti-Laminin IgG2a antibody (C). Labeling of BrdU (green), 
Laminin (red), and DAPI (blue) was used to identify the BrdU-positive nuclei within the muscle 
fibers to estimate the proliferation of muscle satellite cells in 6 non-overlapping fields. The 
number BrdU positive nuclei are shown as a percentage of all muscle nuclei in the plantaris (D) 
and soleus muscles (E). Only the BrdU positive nuclei within the basal lamina were quantified. 
The BrdU labeling index was calculated as the number of BrdU labeled nuclei .  total nuclei-1 . 
100. This provided an index of satellite cell proliferation. The data for the soleus muscles are 
control values only, loading experiments were performed only on plantaris muscles (n=6 for all 
groups). Data presented as means + SE. *, p < 0.05 OZR-7 vs. LZR-7, or OZR-21 vs. LZR-21 
(comparison between control values at same days post surgery). **, p < 0.05 Loaded vs. 
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contralateral control.  Abbreviations: LZR, Lean Zucker rat; OZR, Obese Zucker rat; -7, 7 days 
of loading; -21, 21 days of loading; control, contralateral control. 
 
Figure 5.  Immunoblot analysis of the protein expression levels of the myogenic regulatory 
factors MyoD (A) and myogenin (B) in control and loaded plantaris muscles. Data are expressed 
as optical density x band area normalized to GapDH.  The inset displays representative images 
for control and experimental muscles. Data presented as means + SE. *, p < 0.05 OZR-7 vs. 
LZR-7, or OZR-21 vs. LZR-21 (comparison between control values at same days post surgery). 
**, p < 0.05 loaded vs. contralateral control.  Abbreviations: LZR, Lean Zucker rat; OZR, Obese 
Zucker rat; -7, 7 days of loading; -21, 21 days of loading; control, contralateral control. (n=6 for 
all groups). 
 
Figure 6.  Immunoblot analysis of the protein expression levels of total Akt (A), Akt1 (B), and 
Akt2 (C) isoforms in control and loaded plantaris muscles. Data are expressed optical density x 
band area normalized to GapDH.  Inset displays representative images for control and 
experimental muscles (D). Data presented as means + SE. *= p < 0.05 OZR-7 vs. LZR-7, or 
OZR-21 vs. LZR-21 (comparison between control values at same days post surgery). **, p < 
0.05 Loaded vs. contralateral control.  Abbreviations: LZR, Lean Zucker rat; OZR, Obese 
Zucker rat; -7, 7 days of loading; -21, 21 days of loading; control, contralateral control; OD, 
optical density, a.u., arbitrary units. (n=6 for all groups). 
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Palmitate increases Bax mediated apoptotic signaling C2C12 myotubes 






Mitochondria induced apoptotic signaling in differentiated skeletal muscle in response to 
palmitate treatment has been recently reported in L6 myotubes, but it is unknown if Bax 
signaling contributes to this phenomenon.  Additionally, since palmitate treatment decreases 
growth factor mediated Akt activation, the association of Akt activity and Bax-Bcl-2 binding was 
also examined.  Akt content and phospho-Aktser473 were reduced in C2C12 myotubes after 
treatment with palmitate. This reduction in phospho-Aktser473 activity coincided with increased 
apoptosis in C2C12 myotubes as shown by a 2-fold increase in DNA fragmentation, a ~5-fold 
increase in caspase-3 activity, a 2.5-fold increase in caspase 9 activity, and a 2-fold increase in 
cytochrome c release from the mitochondria.  Furthermore, there was a small but significant 
increase in the amount of the pro-apoptotic protein Bax with palmitate treatment.  To determine 
if palmitate treatment decreased the ability for Bcl-2 to bind and inhibit Bax, an 
immunoprecipitation (IP) assay to Bcl-2 was performed.    IP analysis demonstrated that 
palmitate treatment significantly lowered the binding of Bax to Bcl-2, which in turn allows the 
pro-apoptotic effects of Bax to proceed.  Furthermore, treatment of the C2C12 myotubes with 
Bax siRNA was able to attenuate the apoptotic effects of palmitate treatment.  Together, these 
data show that similar to the L6 cell line, palmitate induces mitochondrial-associated apoptosis in 
C2C12 myotubes.  Our novel finding is that, palmitate treatment corresponded to reductions in 










Obesity increases the risk for heart disease, hypertension and type 2 diabetes mellitus.  
Increased accumulation of intramuscular lipids  without corresponding increases in β-oxidation 
can lead to insulin resistance dyslipidemia and lipotoxicity  Excess lipid accumulation is thought 
to lead to increased oxidative stress and dysfunction in cardiac muscle (15, 17) although the role 
in skeletal muscle has not been well studied. 
Palmitate is the most abundant systemic saturated fatty acid in the circulation, and therefore 
it has been used frequently, to examine the effects of saturated fatty acids in dyslipidemia on 
various tissues (7, 10, 22, 30, 32). Treatment of different cell types with palmitate in vitro has 
resulted in apoptosis (9, 22, 25, 31), and has been found to inhibit Akt/Protein kinase B (Akt) 
activity in response to insulin (6, 7, 27).  However, shorter carbon chained saturated fatty acids, 
i.e. laurate, have been demonstrated not to interfere with Akt signaling (6, 7), but their impact on 
apoptosis has not been examined. 
Although not previously examined in conjunction with palmitate treatment, one of the 
primary ways in which Akt inhibits apoptosis is through control of the B-cell 
leukemia/lymphoma-2 (Bcl-2) family.  Akt signaling acts directly and indirectly to promote the 
binding of the anti-apoptotic protein Bcl-2 to the pro-apoptotic protein Bcl-2 associated X 
protein (Bax) (14, 16, 33). Once Bax is released from Bcl-2, there is a Bax-Bax-oligomerization, 
that inserts into the mitochondrial membrane, and causes mitochondrial permeabilization (33). 
Once the mitochondrial membrane is permeablized, there is a release of proapoptotic factors, 
including apoptosis inducing factor (AIF), Smac/Diablo, and cytochrome c (5, 18).  When free of 
the mitochondria AIF translocate to the nucleus and cause DNA fragmentation independently of 
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caspases. Similarly, cytochrome c is released from the mitochondria and results in the activation 
of caspase-9 and subsequently caspase-3 which leads to DNA fragmentation and cell death (5, 
19).  Lastly, when released from the mitochondria Smac/Diablo attenuates the apoptotic 
inhibitory proteins, such as XIAP (13).  Once released from the mitochondria, these proteins 
function to induce DNA fragmentation and apoptosis.     
Palmitate treatment has been shown to induce apoptosis in L6 myotubes (25), and Bcl-2 
overexpression has been demonstrated to inhibit palmitate induced apoptosis in a non-muscle 
cell lines (9). However, whether palmitate treatment can attenuate the ability of Bcl-2 to bind 
Bax has not been examined.  Therefore, the purposes of this study were to determine if palmitate 
treatment, but not the shorter chain fatty acid laurate: (i) induces apoptotic signaling in mouse 
C2C12 myotubes; (ii) results in the release of mitochondrial apoptotic factors cytochrome c, 
AIF, and smac/Diablo; (iii) attenuates Bax-Bcl-2 binding; (iv) induces apoptosis that is 
dependent on Bax signaling. 
 
Materials and Methods 
 
Cell culture. C2C12 myoblasts were purchased from American Type Culture Collection 
(ATCC, Manassas, VA).  The cells were cultured in 100 mm polystyrene culture dishes in 
Dulbecco Modified Eagle’s Medium (Invitrogen, USA) supplemented with 10% FBS and 1% 
antibiotic antimycotic mixture and passaged in 0.25% trypsin. The cells were maintained in a 
humidified incubator under an atmosphere of 5% CO2 at 37ºC.  For differentiation into 
myotubes, the myoblasts were grown to confluency and transferred to DMEM containing ITS 
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liquid media (Sigma-Aldrich, St. Louis, MO).  Myotubes were used for experiments following 4 
days of differentiation.  All experiments were performed in triplicate. 
 Palmitate (Sigma Chemicals; St. Louis, MO) was administered to cells as described by 
Chavez and Summers (6, 7) with dodecanoic acid (laurate) used as a short chain free fatty acid 
(FFA) to differentiate the effects of  FFAs alone and FFAs which interfere with Akt signaling.  . 
An additional control group received only the media.  Briefly, palmitate was dissolved in ethanol 
and diluted in DMEM containing 2% BSA. C2C12 myotubes were incubated with the FFAs 
(0.75mM final concentration) in 1% FBS–DMEM for 16 h, washed with DHANKS, and then 
incubated with the FFA in serum free DMEM for 2 hours.  1% FBS was reintroduced to the 
media 10 minutes prior to collection, except where indicated.   
siRNA transfection.  The myotubes were transfected with scrambled, nonspecific siRNA 
without mammalian homology, or Bax siRNA (Santa Cruz Biotechnology, Santa Cruz, CA) 
using Lipofectamine 2000 (Invitrogen Carlsbad, CA).  Individual siRNAs (80 
pmols/transfection) were transfected using Lipofectamine in serum-free DMEM for 6 hours.  A 
2x concentration (2%FBS, 4% BSA, and 1.25 mM of palmitate) of media was then added to each 
well and the samples were incubated for an additional 12 hours.   
Cytochrome c Assay.  The extent of cytochrome c that was released from the mitochondria 
was determined in a mitochondrial-free cytoplasmic protein fraction as previously described  
(28).  C2C12 myotubes were collected after treatment in ice-cold extraction buffer in the 
presence of a protease inhibitor cocktail (PIC; Sigma-Aldrich). Briefly, cells were lysed in ice-
cold Mito-buffer (20 mM HEPES pH 7.5, 10 mM KCl, 1.5 mM MgCl2, 1 mM EGTA, 1 mM 
EDTA, 1 mM dithiothreitol, 250 mM sucrose, and 0.1 mM phenylmethylsulfonyl fluoride) by 
homogenization in a small glass homogenizer with Teflon pestle. The homogenates were 
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centrifuged at 800 g to remove nuclei and cell debris and then centrifuged at 16,000 g for 20 min 
at 4°C to pellet the mitochondria. The supernate contained the mitochondrial-free cytosolic 
protein fraction and this used for determining the release of cytochrome c and Smac/Diablo from 
the mitochondria. Purity of the fractions were determine through immunoblot analysis of anti-
MnSOD (a mitochondrial isoform of superoxide dismutase)and anti-CuZnSOD (a cytosolic 
isoform of superoxide dismutase)  as previously performed in our laboratory (28), data not 
shown. 
A cytochrome c ELISA kit (#5265, Medical and Biological Laboratories; Japan) was used to 
assess the protein content of cytochrome c in the mitochondria-free cytosol fraction to evaluate 
the release of the mitochondrial cytochrome c into the cytosol. The change in color was 
monitored at a wavelength of 450 nm using a Dynex MRX plate reader. Measurements were 
performed in duplicate with all comparisons performed with the same assay.  The cytochrome c 
content was analyzed as OD450 per milligram of protein, and then normalized to protein 
concentration. 
Akt/PKB Activity Assay. Akt/PKB activity was determined by an Akt/PKB Kinase Activity 
Kit (EKS-400A; Stressgen, Victoria BC).  Because the basal level of Akt/PKB activity was 
below the sensitivity of the assay, myotubes were first treated with 100 nM of insulin for 10 
minutes before harvesting the cells.   The change in color optical density (OD) was measured at a 
wavelength of 405 nm by using a Dynex MRX plate reader controlled through PC software 
(Revelation; Dynatech Laboratories, CA, USA). Measurements were performed in duplicate. The 
OD405 reading was then normalized to the milligrams of protein used in the assay.    
Nuclear and cytoplasmic protein extracts.  The nuclear and cytoplasmic protein extracts were 
obtained using the method described by Rothermel et al. (26) and performed routinely in our lab 
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(28). Briefly, the cells were washed 3 times in ice-cold phosphate buffered saline (PBS) then 
incubated in lysis buffer (10 mM NaCl, 1.5 mM MgCl2, 20 mM HEPES, pH 7.4, 20% glycerol, 
0.1% Triton X-100, and 1 mM dithiothreitol) for 5 minutes at 4ºC.  The cells were gently 
homogenized in a small glass homogenizer with Teflon pestle. The homogenates were 
centrifuged at 1,000 rpm for 1 min at 4°C. The supernatants contained the cytoplasmic protein 
fraction and were collected. The remaining nuclear pellet was washed twice in lysis buffer and 
then resuspended in lysis buffer containing 0.6 M NaCl. The mixture was incubated for 1 h at 
4°C and centrifuged at 14,000 rpm for 15 min at 4°C. The supernatants contained the nuclear 
protein fraction. The total protein contents of the cytoplasmic extracts were quantified in 
duplicate by using bicinchoninic acid reagents (Pierce, Rockford, IL) and bovine serum albumin 
(BSA) standards.  
A portion of the cytosolic extract (without addition of protease inhibitors) was stored and 
used for fluorometric caspase activity assays, while protease inhibitor cocktail (PIC, Sigma-
Aldrich, St Louis, MO) was added to the nuclear and remaining cytosolic portion for further 
analysis.   
Signaling protein levels were determined by immunoblotting.  Myotubes were washed 3 
times in ice-cold PBS then 1x SDS sample buffer (50 mM Tris-HCl, pH 6.8, 2% SDS, 6% 
glycerol, 1% β-mercaptolethanol, 0.02% bromophenol blue) was added directly to the myotubes. 
2x SDS lysis buffer was added to an equal volume of mitochondrial free cytosolic protein extract 
or nuclear protein extract, respectively.  Samples were lysed with a 25 gauge needle and boiled 
for 5 min at 100°C. Samples were separated on a 4-12% gradient polyacrylamide gel (Invitrogen, 
USA).  Gels were blotted to nitrocellulose membranes (Bio-Rad, Hercules, CA) and stained with 
Ponceau red (Sigma Chemical Co, St Louis, MO, USA) to confirm equal loading. 
CHAPTER 4  Peterson 91  
 
 Membranes were blocked in 5% non-fat milk in Tris buffered saline with 0.05% Tween 
20 (TBS-T) and then probed with primary antibodies, against Akt, and Akt Ser473 
phosphorylation (Cell Signaling Tech.), Bad, Bax, or Bcl-2 (Santa Cruz Biotechnology, Santa 
Cruz, CA), Smac/Diablo, AIF (BD biosciences) and β-tubulin (Abcam, Cambridge, MA) was 
also used a loading control. Secondary antibodies were conjugated to horseradish peroxidase 
(Chemicon, CA, USA) and signals were developed by chemiluminescence (ECL advance, 
Amersham Biosciences) and visualized by exposing the membranes to X-ray films (BioMax MS-
1, Eastman Kodak, Rochester, NY, USA). Digital records of the films were captured with a 
Kodak 290 camera.  The resulting bands were quantified as optical density (OD) x band area by 
a one-dimensional (1-D) image analysis system (Eastman Kodak, Rochester, NY, USA) and 
expressed normalized to ß-Tubulin.  The sizes of the proteins were verified by using standard 
molecular-weight markers (Bio-Rad, Hercules, CA, USA).     
Fluorometric caspase activity assay. Activity of the caspase-9, 3, and 8 were analyzed by a 
commercial caspase assay kit (APO-54A-019-KI01, Apotech, Switzerland) according to the 
manufacturer’s procedure and as previously performed in our laboratory (28).  Caspase-3 and 
caspase-9 were measured as indices of mitochondrial induced apoptosis, whereas caspase 8 is a 
non-mitochondrial dependent caspase. 
Briefly, the cytosolic extract  without protease inhibitor was incubated in an equal volume of 
assay buffer (50 mM PIPES, 0.1 mM EDTA, 10% glycerol, 10 mM DTT, pH 7.2) with 100 µM 
of the fluorogenic 7-amino-4-trifluoromethyl coumarin (AFC)-conjugated substrate (Ac-DEVD-
AFC, Alexis Corp., San Diego, CA, USA) at 37°C for 2 h. The change in fluorescence was 
measured on a spectrofluorometer with an excitation wavelength of 390/20 nm, and an emission 
wavelength of 530/25 nm (CytoFluor; Applied Biosystems, Foster City, CA, USA) before and 
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after the 2 h incubation. Caspase activity was estimated as the change in mean fluorescence 
intensity (MFI) expressed as arbitrary units normalized to protein concentration. Measurements 
were performed in triplicate. 
DNA fragmentation.  A cell death detection ELISA kit (Roche Applied Science, Indianapolis, 
IN, USA) was used to quantitatively determine the apoptotic DNA fragmentation by measuring 
the cytosolic histone-associated mono- and oligonucleosomes. The change in optical density 
(OD) was measured at a wavelength of 450 nm by using a Dynex MRX plate reader controlled 
through PC software (Revelation; Dynatech Laboratories, CA, USA). Measurements were 
performed in duplicate, with samples from OZR and LZR analyzed at the same time. The OD450 
reading was then normalized control samples. Measurements were performed in triplicate. 
Bax and Bcl-2 binding.  To determine if Bax to Bcl-2 binding corresponded to Akt Ser473 
phosphorylation, myotubes were serum starved for two hours with or without the addition of a 
commercially available Akt inhibitor (124005, Calbiochem, Germany). 1% FBS was 
reintroduced to the media 10 minutes before collection of the myotubes.  Similarly, to determine 
if the binding of Bax to Bcl-2 was altered with palmitate treatment, Bcl-2 was 
immunoprecipitated and the binding of Bax was determined through immunoblot analysis.  
After treatment, myotubes were harvested in CHAPS buffer (40 mM HEPES, pH 7.5, 120 
mM NaCl, 1 mM EDTA, 10 mM pyrophosphate, 10 mM -glycerolphosphate, 40 mM NaF, 1.5 
mM sodium vanadate, 0.3% CHAPS, 0.1 mM PMSF, 1 mM benzamidine, and 1 mM DTT), 
rocked for 20 min at 4°C and then centrifuged at 1,000 g for 10 min at 4°C. An aliquot from the 
resulting supernatant was preserved as total protein.  The remaining supernatant was incubated 
with anti-Bcl-2 (0.2 µg/100 µl; Santa Cruz), and incubated overnight at 4°C. Prior to analysis, the 
immune complexes were collected for 1 h at 4°C with a goat anti-mouse BioMag IgG (Quigen, 
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310004) beads, blocked with 0.1% nonfat dry milk in CHAPS buffer.  The beads were collected 
using a magnetic stand and washed with 200 mM CHAPS and 60 mM HEPES. The precipitates 
were eluted in 5x SDS sample buffer (250 mM Tris-HCl pH 6.8, 10% SDS, 30% Glycerol, 5% 
β-mercaptoethanol and 0.02% bromophenol blue) and then boiled for 5 min. The beads were 
collected with a magnetic stand, and the supernatant was collected and subjected to SDS-PAGE. 
Statistical analyses. Statistical analyses were performed using the SPSS 10.0 software package. 
A one way Analysis of variance (ANOVA) was performed on the difference in all measured 




Palmitate attenuated Akt signaling. To determine the ability of palmitate pre-treatment to 
inhibit Akt phosphorylation, serum was removed from the media for 2 hours, and then FBS was 
reintroduced into the media (final concentration was 1% FBS) for 10 minutes.  Representative 
blots for total Akt, Akt1, Akt2, and Akt Ser473 phosphorylation protein expression levels are 
shown in Figure 1A with control, laurate, or palmitate treatment.  Total Akt was reduced by 30 + 
3% in palmitate treated myotubes compared to control or laurate treated myotubes.  There was 
also a 41 + 7% decrease in Akt Ser473 phosphorylation in palmitate treated myotubes. In a 
separate experiment, palmitate treatment resulted in a 33 + 3% decrease in overall Akt activity in 
response to 100 nM insulin (Figure 1B).   
Palmitate increased Bax protein concentration. To determine if palmitate treatment affected 
the Bcl-2 family protein expression levels, these proteins were examined through immunoblot 
analysis. There was no change in content of the pro-apoptotic protein Bad, nor was there any 
change in the concentration in the content of the anti-apoptotic protein Bcl-2. However, there 
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was a small increase, ~20%, in the protein content of the pro-apoptotic protein Bax (Figure 2).  
These data may indicate that the actions of palmitate treatment may be dependent on the increase 
of the Bax protein.   
Palmitate induced release of mitochondrial apoptotic proteins.  The proteins cytochrome c, 
AIF, and Smac/Diablo all contribute to apoptotic signaling when they are released from the 
mitochondria into the cytoplasm.  The addition of palmitate to the myotubes increased the 
cytoplasmic content of cytochrome c 2-fold compared to control treatments (Figure 3A).  In 
addition, palmitate treatment also increased the release of Smac/Diablo and AIF from the 
mitochondria (Figure 3B).   
Palmitate increased Caspase Activity. Palmitate treatment also resulted in a 5-fold increase 
in caspase-3 activity, a 2.5 fold increase in caspase-9 activity, with no change in caspase 8 
activity (Figure 4).  These data indicate palmitate induced mitochondria-dependent caspase 
signaling because caspase-9 activation is dependent on release of cytochrome c from the 
mitochondria, whereas caspase 8 is activated independently of mitochondria outer membrane 
permeabilization.   
Palmitate induced DNA fragmentation. Because caspase-3 is the effector caspase which, 
when activated cleave DNA, we measured DNA fragmentation in C2C12 myotubes. Palmitate 
and laurate treatment induced a 7-fold and 3-fold increase in DNA fragmentation, respectively, 
compared to control treatment (Figure 5). Palmitate treatment generated a 2.5-fold increase in 
DNA fragmentation compared to the shorter chained saturated FFA laurate (Figure 5). 
Palmitate induced Bax signaling. Since Akt signaling is significantly reduced with palmitate 
treatment, but not laurate, and Akt signaling can contribute to the control of Bax to Bcl-2 
binding, an immunoprecipitation to Bcl-2 was performed in the presence or absence of 1% FBS 
CHAPTER 4  Peterson 95  
 
and the binding of Bax to Bcl-2 was determined.  In control samples, the addition of FBS 
increased the amount of Akt Ser473 phosphorylation ~50 fold and corresponded to an increase 
binding of Bax to Bcl-2 of ~10-fold compared to serum starved samples (Figure 6A).  However, 
treatment of samples with palmitate, but not laurate, greatly attenuated the Bax to Bcl-2 binding 
in response to FBS (Figure 6B).  
Bax siRNA attenuated palmitate mediated apoptosis. As expected, treatment with Bax siRNA 
reduced Bax protein content in both control and palmitate treated myotubes (Figure 7A).  The 
reduction in Bax protein expression with siRNA attenuated the increase in DNA fragmentation 
and caspase activity that otherwise occurred after palmitate treatment (Figure 7B-D).  In 
addition, we noted that the siRNA transfection protocol induced a 2-fold increase in DNA 




The novel findings of this study are: (i) both palmitate and laurate treatment increased DNA 
fragmentation indicating that saturated FFA can induce apoptosis (ii) palmitate, but not laurate, 
treatment increased mitochondria mediated apoptosis in C2C12 myotubes as indicated by 
increased the release of cytochrome c, Smac/Diablo, and AIF from the mitochondria indicating 
both caspase dependent and caspase independent apoptotic mechanisms with palmitate 
treatment; (iii) palmitate, but not laurate, treatment inhibited Akt activity and attenuated the 
ability of FBS to increase Bax-Bcl-2 binding in C2C12 myotubes; and (iv) knock down of Bax 
protein significantly attenuated the ability of palmitate treatment to induced apoptosis in C2C12 
myotubes. Pre-treatment of C2C12 myotubes with palmitate has been used to mimic aberrant 
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lipid signaling. which is one particular aspect common with metabolic syndrome and type 2 
diabetes (6, 7, 9, 25, 27). Palmitate, and other long chain saturated FFAs, result in increased 
formation of ceramide, which inhibits Akt activity, whereas laurate and other saturated short 
chain FFAs do not result in ceramide accumulation or Akt inhibition (6, 7, 21).  This is 
noteworthy because ceramide levels are elevated in insulin-resistant humans subjects (1). 
Because Akt signaling is both disrupted with metabolic syndrome (6, 7) and has a major role in 
inhibiting apoptosis (11, 12, 16), we hypothesized that palmitate would decrease Akt 
phosphorylation and activate mitochondrial-associated apoptotic signaling in mouse C2C12 
myotubes.  Specifically, we hypothesized that palmitate would increase mitochondrial-associated 
apoptosis through attenuation of Bax to Bcl-2 binding.   
It has been well documented that skeletal muscle apoptosis is an integral part of skeletal 
muscle loss with aging (2, 29);  the role of skeletal muscle apoptosis in metabolic syndrome has 
not been examined. Palmitate treatment has recently been shown to induce mitochondrial DNA 
damage and apoptosis in L6 myotubes (25), however this study did not determine whether a 
shorter carbon chain FFA, such as laurate, would also induced DNA damage or apoptosis.  In our 
hands, both laurate and palmitate resulted in increased DNA damage.  Nevertheless, palmitate 
resulted in augmented apoptotic signaling compared to laurate treatment, signifying that 
palmitate treatment induces additional apoptotic signaling compared to shorter FFAs.  It is likely 
that the decrease in Akt signaling after palmitate treatment contributes to the increase in 
apoptosis when compared to laurate treatment. However, it is also possible that palmitate, or its 
metabolites, allosterically interfere with Bax and Bcl-2 binding.  These possibilities are both 
supported by our data, but either situation supports our hypotheses that palmitate induces 
mitochondrial apoptosis and that it is dependent on Bax signaling.  
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Mitochondrial associated apoptosis in C2C12 cells. When the mitochondrial outer 
membrane is permeabilized, it releases proapoptotic factors, such as AIF, Smac/Diablo, and 
cytochrome c, each of which can independently increase apoptosis (5, 18). When released from 
the mitochondria, AIF translocates to the nucleus where it can cleave the DNA directly.  
Smac/Diablo, binds and prevents the actions of a number of apoptosis inhibitory proteins.  In 
contrast, cytochrome c forms a complex with Apaf-1 and pro-caspase-9 to form the apoptosome.  
The apoptosome cleaves pro-caspase-9 into its active form.  Caspase-9 then activates caspase-3, 
an apoptotic effector that leads to DNA fragmentation and cell death (5, 19). The results of the 
present study confirm that palmitate treatment increased nuclear apoptosis in C2C12 cells. This 
was confirmed through increases in nuclear levels of AIF, increased cytoplasmic levels of 
cytochrome c and Smac/Diablo, and elevated caspase-9 and -3 activity levels, and lastly, 
increased DNA fragmentation (Figures 3-5). The reason for increased DNA fragmentation with 
laurate treatment compared to controls is unknown, but may be due to increased lipid oxidation 
(20, 31). Nevertheless, the increase in DNA fragmentation with laurate treatment is independent 
from any apoptotic signaling mechanisms examined in this study.  
Bax: Bcl interactions in palmitate treatment. The primary novel finding of this study was that 
palmitate treatment, attenuated the ability of growth-factor-rich serum (FBS) to increase Bax-
Bcl-2 binding (Figure 6B). When growth factors were removed from the culture medium, Bax 
was dissociated from Bcl-2 but this was quickly reversed (~10 min post treatment) when growth-
factor-rich serum was reintroduced to the culture medium (Figure 6A). The pattern of Bax and 
Bcl-2 during palmitate treatment coincides with the amount of Akt phosphorylation. In addition 
the Bax-Bcl-2 binding was prevented when an Akt inhibitor was added to the media. This 
supports the hypothesis that Akt directly acts on Bax to increase its binding to Bcl-2 (8). Once 
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Bax is released from Bcl-2 there is a Bax-Bax-oligomerization. This Bax-Bax protein complex 
then inserts into the outer mitochondrial membrane, causing mitochondrial permeabilization and 
release of proapoptotic factors: AIF, Smac/Diablo, and cytochrome c (33). The release of these 
proteins from the mitochondria results in DNA fragmentation and loss of the nucleus (5, 19).  
Although the loss of only a few nuclei will not result in elimination of the entire myotube, the 
loss of sufficient numbers of nuclei in a single myotube would result in cell death. 
Metabolic syndrome is the most prevalent metabolic health risk in the world, affecting more 
than 47 million Americans (23). Skeletal muscle is an important target tissue in the study of 
metabolic syndrome as it accounts for more than half of total body insulin resistance, and is also 
a key tissue for lipids uptake and oxidation (3, 4, 24). Therefore, the loss of skeletal muscle can 
further exacerbate the risks associated with metabolic syndrome.  In this study C2C12 myotubes 
were used as an in vitro model of skeletal muscle and palmitate was used to mimic one aspect 
common in metabolic syndrome, dyslipidemia.  This study demonstrated that long chain 
saturated fatty acids, i.e. palmitate, can reduce Akt signaling and increase Bax-mediated 
mitochondrial induced apoptosis.  These findings indicate that people with metabolic syndrome 
may have increase apoptotic signaling and underscores the need for in vivo studies examining the 
effects of Akt signaling, skeletal muscle apoptosis, and metabolic syndrome. 
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Figure 1: A) Akt protein and Akt Ser473 phosphorylation expression in C2C12 myotubes.  
Palmitate treatment significantly reduced the protein expression of Akt as well as Akt Ser473 
phosphorylation.  Graph shows mean + SE presented as optical density (OD) x area expressed in 
arbitrary units.  B) Akt activity in C2C12 myotubes.  Samples were treated overnight in 1% FBS, 
then incubated for 2 hours in serum free media.  10 minutes before collection 100 nM of insulin 
was added to the media.  Palmitate treatment significantly reduced the activity level of Akt.  Data 
was normalized to total protein content *p < 0.05 verse control samples. 
 
Figure 2: Bcl-2, Bax, and Bad protein expression in C2C12 myotubes.  Palmitate had no effect 
on either Bcl-2 or Bad protein expression.  However, palmitate treatment significantly increased 
the amount of Bax protein expression in C2C12 myotubes.  The data are expressed as optical 
density (OD) x area (in arbitrary units) and they are displayed as mean ± SE.  *p < 0.05 vs. 
control samples. 
 
Figure 3: Apoptotic signaling proteins released from the mitochondria.  Palmitate treatment 
significantly increased the release of Cytochrome c (A), Smac/Diablo, and apoptosis inducing 




Figure 4: Caspase Activity Assay Figure in C2C12 myotubes.  Palmitate treatment significantly 
increased caspase-3 and 9 activity. The data are expressed as fluorescent intensity (MFI) per µg 
protein and they are displayed as mean ± SE.  *p < 0.05 vs. control samples. 
 
Figure 5: DNA fragmentation in C2C12 myotubes.  Palmitate treatment significantly increased 
the content of fragmented DNA as determined by a cell death ELISA assay. The data are 
expressed as optical density (OD) x area (in arbitrary units) and they are displayed as mean ± SE.  
*p < 0.05 vs. control samples. 
 
Figure 6: Bcl-2 immunoprecipitation assay of control samples or with the addition of the Akt 
inhibitor (A) with and without 1% FBS added following 2 hours of serum starvation.  B) After 
treatment with palmitate for 20 hours there was a significant decrease in the amount of Bax 
protein that was bound to Bcl-2 with the re-introduction of serum to the media. The data are 
expressed as optical density (OD) x area (in arbitrary units) and they are displayed as mean ± SE.  
*p < 0.05 vs. control samples. 
 
Figure 7: Bax protein expression with Bax or scrambled siRNA and control or palmitate 
treatments (A).   Bax siRNA attenuated palmitate induced apoptotic signaling as shown by 
decreased DNA fragmentation (B), decreased caspase 3 activity (C), and  decreased caspase 9 
activity (D). The data are expressed as optical density (OD) x area (in arbitrary units) and they 
are displayed as mean ± SE.  *p < 0.05 vs. Scramble siRNA treated control sample. ** p < 0.05 
vs. scrambled siRNA-palmitate treated sample. 
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MITOCHONDRIAL APOPTOTIC SIGNALING IS ELEVATED IN CARDIAC BUT 
NOT SKELETAL MUSCLE IN THE OBESE ZUCKER RAT AND IS REDUCED 
WITH AEROBIC EXERCISE 




Cardiac and skeletal muscles are both negatively affected by factors linked to metabolic 
syndrome including insulin resistance and obesity.  Metabolic syndrome has been associated 
with increased mitochondrial apoptosis in cardiac tissue; however, the incidence of 
mitochondrial apoptosis in skeletal muscle with metabolic syndrome has not been examined. 
In this study we examined the effect of obesity and insulin resistance on key proteins 
regulating mitochondrial apoptosis in the cardiac and skeletal muscles and their response to 
aerobic training.  For this study the left ventricle, the soleus, and gastrocnemius muscles were 
examined from 16 obese Zucker rats (OZR) and aged matched lean Zucker rats (LZR). Eight 
animals of each phenotype were aerobically trained on a treadmill for 9 weeks; the remaining 
animals were untrained controls. Cardiac Bcl-2 protein expression level was ~50% lower in 
the OZR compared with the LZR, with no difference in either of the skeletal muscles. Bax 
protein expression levels were similar in the cardiac and skeletal muscles of the OZR 
compared to the LZR.  However, there was a ~7-fold increase in the Bax protein 
accumulation in the myocardial mitochondrial protein fraction of the OZR compared to the 
LZR.  Furthermore, there was an increase in cytochrome c released from the mitochondria, 
and a corresponding increase in caspase-9 and caspase-3 activity in the cardiac muscles of 
the OZR compared to the LZR.  Moreover, DNA fragmentation was elevated ~2-fold in the 
cardiac muscles of the OZR, indicating increased apoptosis. There was no change in 
cytosolic cytochrome c, caspase activity, or DNA fragmentation in the skeletal muscles of 
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the OZR compared to the LZR.  Aerobic exercise training reduced Bax protein expression 
levels in both LZR and OZR animals and increased Bcl-2 protein expression levels in the 
OZR in the cardiac muscles. Furthermore, cytosolic cytochrome c, caspase activity, and 
DNA fragmentation were all reduced in the cardiac muscle of the OZR after exercise, with 
no change in the skeletal muscles.  Combined these data show that mitochondrial apoptosis is 
elevated in the cardiac but not skeletal muscles of the OZR, but aerobic exercise training was 
effective in reducing cardiac mitochondrial apoptotic signaling. 
 
KEY WORDS: Insulin resistance, Bax, Bcl-2, mitochondrial signaling, muscle wasting 




Apoptosis is a highly organized and tightly coordinated biological process, which 
plays a vital role in monitoring a variety of non-pathological cellular events (e.g., tissue 
turnover).  Aberrant regulation of apoptosis has been implicated in the pathogenesis of 
certain severe muscle-related diseases including Duchenne and facioscapulo human muscular 
dystrophy (21).  The molecular events resulting in the activation and subsequent execution of 
the apoptotic program is principally controlled under the simultaneous influence of both pro- 
and anti-apoptotic signaling which are primarily regulated by specific apoptotic regulatory 
proteins.  
The B-cell leukemia/lymphoma-2 (Bcl-2) family of upstream regulators of apoptosis 
are crucial intracellular checkpoint proteins in the apoptotic signaling pathway (9, 10, 18). 
BCL-2 family members, Bcl-2 associated X (Bax) protein and Bcl-2 have been identified as 
the main proteins involved in the regulation of mitochondrial-associated apoptotic signaling 
particularly as they relate mitochondrial ion channel forming activities. Bax has been 
demonstrated to translocate to the mitochondria and expose its N-terminus via a 
conformational change upon induction of apoptosis (2, 4, 8, 14, 18, 29). This conformational 
change permits the Bax-Bax-oligomerization and insertion of Bax into the outer 
mitochondrial membrane (31), which is followed rapidly by the release of the apoptogenic 
factors (e.g., cytochrome c) from the mitochondrial intermembrane space (6, 7, 16). 
Collectively, Bax oligomerization is thought to be critical for mitochondrial membrane 
permeabilization whereas Bcl-2 opposes the pro-apoptotic activity of Bax by preventing Bax-
Bax-oligomerization (2, 18, 31). Although the precise mechanism of Bax-mediated 
apoptogenic factor release from the mitochondrial intermembrane space is still under active 
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investigation, it is indisputable that Bax plays an important role in promoting the activation 
of apoptotic signaling cascades.  
Mitochondrial-associated apoptotic signaling including an elevation in the Bax/Bcl-2 
ratio has been implicated in muscle wasting and aging-associated losses of skeletal muscle 
(1, 23). The obese Zucker (fa/fa) rat (OZR) is used as an animal model for metabolic 
syndrome because it exhibits severe skeletal muscle insulin resistance, hyperglycemia, and 
hyperlipidemia (12, 32). Recently, myocardial mitochondrial apoptosis has been 
demonstrated to be elevated in this model of metabolic syndrome (15, 17).  However, 
although the skeletal muscles of the OZR are smaller than the lean zucker rats (LZR), 
mitochondrial apoptotic signaling has not been examined in this model Although, metabolic 
syndrome has not been linked to skeletal muscle apoptosis it has been linked to skeletal 
muscle atrophy (3), additionally, metabolic syndrome has been associated with increased 
apoptosis in cardiac tissue (5, 15, 17). It is possible that increased Bax/Bcl-2 ratio, with 
metabolic syndrome, contributes to increase susceptibility to apoptosis in cardiac as well as 
atrophy in skeletal muscles.  
The first purpose of this study was to confirm an increase in mitochondrial apoptotic 
signaling in the cardiac muscles of the OZR compared to the LZR and to determine if 
mitochondrial apoptotic signaling is elevated in the skeletal muscles of the OZR compared to 
the lean phenotype.  Furthermore, our lab has previously demonstrated that aerobic exercise 
training can reduce apoptotic signaling in both skeletal and cardiac muscles (24).  However 
the effects of exercise on mitochondrial apoptotic signaling, in a model of metabolic 
syndrome, have not been examined in either cardiac or skeletal muscles.   Therefore, the 
second purpose of this study was to determine if aerobic exercise training would reduce 
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mitochondrial apoptotic signaling in the cardiac and/or skeletal muscles of the OZR model of 
metabolic syndrome.   
 
Materials and Methods 
 
Animals 
OZR (n=16) and LZR (n=16) (Harlan, Indianapolis, IN) were housed in pathogen-free 
conditions, at 20-22°C with a reversed 12:12-h light-dark cycle, and fed rat chow and water 
ad libitum throughout the study period.  The institutional animal use and care committee from 
West Virginia University School of Medicine approved all experiments. The animal care 
standards were followed by adhering to the recommendations for the care of laboratory 
animals as advocated by the American Association for Accreditation of Laboratory Animal 
Care and fully conformed to the Animal Welfare Act of the U.S. Department of Health and 
Human Services.  
 
Treadmill exercise   
Both the OZR and LZR were randomly assigned into equal groups of sedentary (OZR, n=8; 
LZR, n=8) or exercise-trained (OZR-ET, n=8; LZR-ET, n=8). The exercise-trained animals 
were trained by running on a motorized rodent treadmill (Columbus Instruments, Columbus, 
OH) 5 days weekly for 9 wk at 0% grade.  During the first 3 wk of training, the animals 
began 15 minutes at a speed of 10m/min, which was gradually increased to 55 min/day at 20 
m/min for the OZR-ET and 24 m/min for the LZR-ET. This pace was maintained for the 
remainder of the study. Because the OZR animals are heavier, the same running pace would 
result in more total work than the lighter LZR. The higher training intensity for the LZR was 
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to attempt to match the training intensity of the LZR-ET to the much heavier OZR-ET (~40% 
increase in body weight). We have previously shown that this training protocol stimulates a 
moderate endurance training effect with a similar  ~25% increase in citrate synthase activity 
in both the OZR-ET and LZR-ET (12). 
 
Muscles examined 
Muscles from control and exercise-trained animals were harvested after anesthetizing the 
animals with 2% isoflurane. The gastrocnemius and soleus muscles from each limb were 
dissected from the surrounding connective tissues, and 4–5 mm of the left ventricle were 
quickly removed and frozen immediately in liquid nitrogen and stored at –80°C until further 
analysis. 
 
Western Blots   
Total Protein homogenates were prepared in lysis buffer (20 mM Tris pH 7.5, 150 mM NaCl, 
1% Nonidet P-40, 0.5% Sodium Deoxycholate, 1 mM EDTA, 0.1% SDS) with the addition 
of Protease inhibitor cocktail (PIC; Sigma). Separate mitochondrial and mitochondria free 
protein fractions were also prepared according to methods as previously performed in our lab 
(25).  Briefly, samples were homogenized in mitochondrial isolation buffer (20 mM HEPES 
pH 7.5, 10 mM KCl, 1.5 mM MgCl2, 1 mM EGTA, 1 mM EDTA, 1 mM dithiothreitol, 250 
mM sucrose) with protease inhibitor cocktail (Sigma-Aldrich, St Louis, MO, USA). The 
homogenates were centrifuged at 800 x g to remove nuclei and cell debris followed by 
centrifugation at 16,000 x g for 20 min at 4°C to pellet the mitochondria. The supernatants 
were used as mitochondria-free cytosol. The mitochondrial pellet was washed twice then 
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resuspended in total protein lysis buffer for analysis of Bax associated with the mitochondrial 
membrane. 
Protein contents were quantified in duplicate by using bicinchoninic acid reagents 
(Pierce, Rockford, IL, USA) and bovine serum albumin (BSA) standards. 50 µg of soluble 
protein was boiled for 4 min at 100°C in Laemmli buffer and separated on a 4-12% gradient 
polyacrylamide gel (Invitrogen, USA).  The gels were blotted to nitrocellulose membranes 
(Bio-Rad, Hercules, CA, USA) and stained with Ponceau red (Sigma Chemical Co, St Louis, 
MO, USA) to confirm equal loading and transferring of proteins to the membrane in each 
lane. 
 The membranes were then blocked in 5% non-fat milk in Tris buffered saline with 
0.05% Tween 20 (TBS-T) and probed with anti-Bcl-2 or Bax antibodies (Santa Cruz, CA, 
USA).  Additionally, as a second means of confirming equal loading, the membranes were 
also probed for ß-Tubulin (Abcam, MA, USA). Secondary antibodies were conjugated to 
horseradish peroxidase (Chemicon, CA, USA) and the signals were developed by 
chemiluminescence (ECL advance, Amersham Biosciences).  The signals were visualized by 
exposing the membranes to X-ray films (BioMax MS-1, Eastman Kodak, Rochester, NY, 
USA), and digital records of the films were captured with a Kodak 290 camera.  The 
resulting bands were quantified as optical density (OD) x band area by a one-dimensional (1-
D) image analysis system (Eastman Kodak, Rochester, NY, USA) and expressed in arbitrary 
units normalized to ß-Tublin.   
 
Cytochrome c Assay   
The concentration of cytochrome c in the mitochondrial-free cytosol was measured 
with an ELISA kit (Medical and Biological Laboratories; Japan).  The change in color was 
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monitored at a wavelength of 450 nm using a Dynex MRX plate reader. Measurements were 
performed in duplicate with all comparisons performed with the same assay.  The 
cytochrome c content was expressed as OD450 per milligram of protein and reported as 
relative to LZR control values. 
 
Fluorometric caspase activity assay  
To determine whether changes in Bax or Bcl-2 resulted in any downstream apoptotic 
events the activity of caspase-3 and caspase-9 were analyzed by a commercial caspase assay 
kit (APO-54A-019-KI01, Apotech, Switzerland) according to the manufacturer’s procedure 
and as previously performed in our laboratory (24).  Briefly, 50 mg of muscle samples were 
gently homogenized with a Teflon pestle on ice in 1 ml of nuclear isolation lysis buffer (10 
mM NaCl, 1.5 mM MgCl2, 20 mM HEPES, pH 7.4, 20% glycerol, 0.1% Triton X-100, and 1 
mM dithiothreitol). The homogenates were centrifuged at 1,000 rpm for 1 min at 4°C. The 
supernatants contained the cytoplasmic protein fraction and were collected.  The cytoplasmic 
protein fraction was then used for the caspase activity assays and also for the cell death 
ELISA. 
Samples were mixed in equal parts assay buffer (50 mM PIPES, 0.1 mM EDTA, 10% 
glycerol, 10 mM DTT, pH 7.2) and then 100 µM of the fluorogenic 7-amino-4-
trifluoromethyl coumarin (AFC)-conjugated substrate (Ac-DEVD-AFC, Alexis Corp., San 
Diego, CA, USA) was added at 37°C for 2 h. The change in fluorescence was measured on a 
spectrofluorometer with an excitation wavelength of 390/20 nm, and an emission wavelength 
of 530/25 nm (CytoFluor; Applied Biosystems, Foster City, CA, USA) before and after the 2 
h incubation. Caspase activity was estimated as the change in arbitrary fluorescence units 
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normalized to milligrams of protein used in the assay and data was reported relative to LZR. 
All measurements were performed in triplicate.   
 
Cell Death ELISA 
A cell death detection ELISA kit (Roche Applied Science, Indianapolis, IN, USA) 
was used to quantitatively determine the apoptotic DNA fragmentation by measuring the 
cytosolic histone-associated mono- and oligonucleosomes. The change in color was measured 
at a wavelength of 450 nm by using a Dynex MRX plate reader controlled through PC 
software (Revelation; Dynatech Laboratories, CA, USA). Measurements were performed in 
duplicate, with samples from OZR and LZR analyzed at the same time. The OD450 reading 
was then normalized to the milligrams of protein used in the assay. 
 
Statistical analyses  
Statistical analyses were performed using the SYSTAT 11.0 software package. A one 
way Analysis of variance (ANOVA) was performed on the difference in all measured 





Animal Characteristics  
Fasting blood glucose, insulin, body weight, citrate synthase activity, and mean 
arterial blood pressure  have been reported previously (12).  These data show that the OZR 
used in our study were obese, hyperinsulinemic, hyperglycemic, and hyperlipidemic.  This is 
consistent with previous studies which observed similar traits in these animals (3, 32).  
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Briefly, Nine weeks of treadmill exercise reduced body mass by ~23%, reduced fasting 
insulin by ~38%, and reduced plasma triglycerides by ~34% in EX-OZR vs. sedentary (SED) 
OZR (12).  Additionally, the nine weeks of treadmill exercise use in this study increased 
citrate synthase activity ~40% in both phenotypes (12). The mass of the heart, gastrocnemius, 
and soleus muscles are reported in Table 1. 
 
Bax protein contents 
Bax levels were comparable in cardiac and skeletal muscles of OZR and LZR 
animals. However, aerobic exercise reduced Bax levels in the cardiac muscles of the OZR by 
35% (Figure 1A). On the other hand, no differences were observed in Bax protein content of 
the skeletal muscles either between animal phenotype or between exercise training in either 
the gastrocnemius or soleus muscles.    
 
Bcl-2 protein contents 
Representative western blots and the quantified optical density and areas of the 
protein bands of the anti-apoptotic protein Bcl-2 are shown in Figure 1B.   In the heart, Bcl-2 
protein expression in the OZR was about half of the Bcl-2 found in the LZR. Additionally, 
exercise training increased Bcl-2 protein expression in the OZR hearts by approximately 
25%.  On the other hand, no differences were observed in Bcl-2 content of the skeletal 
muscles between LZR and OZR in either the gastrocnemius or soleus muscles.  Moreover, 
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The ability for Bcl-2 to inhibit the activity of Bax is dependent on the ratio of these 
two proteins.  When Bax is in excess, Bcl-2 cannot bind and sequester all the Bax, thus 
allowing more Bax to act on the mitochondrial membrane.  In the heart there was a 2-fold 
increase in the ratio of Bax to Bcl-2 in the OZR compared to LZR (Figure 1C).  Aerobic 
exercise had a trend towards a decrease in this ratio in the heart of the trained OZR vs. 
control OZR (p=0.072).  No differences were observed in the Bax to Bcl-2 ratio in either the 
soleus or the gastrocnemius muscles among the groups. 
 
Mitochondrial Bax accumulation 
To determine if changes in Bax/Bcl-2 ratios resulted in an increase accumulation of 
Bax to the mitochondrial membrane of the heart, the mitochondrial protein was isolated in 
samples taken from the myocardium. There was a large accumulation of Bax in the 
myocardial mitochondrial protein fraction (Figure 3A) of OZR compared to LZR.  The 
amount of Bax associated with the mitochondrial protein fraction was reduced in the exercise 
trained OZR, although there was still a significant accumulation when compared to the LZR.  
On the other hand there was no observable accumulation of Bax in the isolated mitochondrial 
protein fraction from either the soleus or gastrocnemius muscles regardless of phenotype 
(data not shown). 
 
Cytochrome c ELISA 
Increased permeability of mitochondrial membranes and opening of the 
mitochondrial permeability pore results in cytochrome c release from the mitochondria to the 
cystosol. Increased cytosolic cytochrome c has been attributed to caspase-dependent 
apoptosis (7).  The non-mitochondrial cytosolic protein fractions of cardiac muscles from the 
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OZR had a small but significant, ~30%, increase in cytochrome c compared to the LZR 
(Figure 5).  Aerobic training abolished this increase in cytochrome c accumulation in the 
cystosol in cardiac muscles samples of the OZR when compared to the LZR.  No differences 
were noted in the amount of cytochrome c in the mitochondria-free cytosolic protein fraction 
between the OZR and LZR in the gastrocnemius muscles or soleus muscles.  
 
Caspase activity 
Caspase 3 and caspase 9 activities were examined to confirm the significance of 
increases in the Bax to Bcl-2 ratio in downstream mitochondrial apoptotic signaling in the 
cardiac muscle samples. When the mitochondrial membrane is permeablized and cytochrome 
c is released, cytochrome c in turn activates caspase 9.  When activated, caspase 9 in turn 
activates caspase 3 an effector caspase which causes DNA fragmentation and apoptosis.  In 
this study, both caspase 3 and caspase 9 were elevated by more than 30% in the cardiac 
muscle samples of the OZR compared to LZR.  Exercise training in the OZR returned the 
activity level of both caspases to levels found in the LZR. 
 There was a significant elevation of both caspase 3 and caspase 9 activities in the 
denervated gastrocnemius muscles compared to the intra-animal control muscle. Similar to 
the Bax and Bcl-2 protein data, there was no difference in the extent of these changes 
between the LZR and OZR. 
 
Cell Death ELISA 
To determine whether the observed changes in apoptotic signaling resulted in cell 
death, DNA fragmentation was quantified in the cardiac and denervated gastrocnemius 
muscles.  In the cardiac muscle there was a ~40% increase in DNA fragmentation in the OZR 
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compared to the LZR.  Exercise training reduced DNA fragmentation in cardiac muscle 
samples from the OZR to levels similar to the LZR (Figure 8A).  Exercise training had no 




The important finding of this study is that Bax-mediated mitochondrial apoptotic 
signaling is elevated in the cardiac but not skeletal muscles of the OZR.  This finding was 
supported by both an increased Bax to Bcl-2 ratio and an increased Bax protein in the 
mitochondrial protein fraction of the cardiac but not skeletal muscles of the OZR. 
Furthermore, apoptotic signaling downstream of the mitochondria including cytoplasmic 
cytochrome c and caspase 3 and 9 activities were also all elevated in cardiac muscle samples, 
as was the level of DNA fragmentation.   Furthermore, 9 weeks of treadmill training reduced 
apoptotic signaling in the cardiac muscle but had no effect in the skeletal muscles of the 
OZR.   
It is estimated that the prevalence of metabolic syndrome is greater than 20 percent of 
the population in the Unites States (11). Similar to subjects with metabolic syndrome, the 
OZR suffers from hyperglycemia, dyslipidemia, and hyperinsulinemia (12, 32).  Diabetic 
conditions, including hyperglycemia, dyslipidemia, and hyperinsulinemia, have been 
demonstrated to cause mitochondrial membrane hyper-polarization and the formation of 
reactive oxygen species and apoptosis in cardiac (5, 7, 13, 30) and smooth muscles (27, 28).  
Although apoptosis has not been previously examined in diabetic skeletal muscle, we 
hypothesized that apoptotic signaling would be similar in skeletal muscle and cardiac muscle. 
Since apoptosis is elevated in response to various diabetic conditions, we expected to see 
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increased presence of the mitochondrial apoptotic markers Bax, Bcl-2, and cytosolic 
cytochrome c in cardiac and skeletal muscles of the OZR as compared to LZR. Furthermore, 
because endurance exercise has been shown to attenuate apoptotic signaling (24) we 
anticipated a reduction in apoptotic signaling in cardiac and skeletal muscles of OZR with 9-
weeks of treadmill training.   
 
 
Bax, Bcl-2 and Bax/Bcl2 ratios in cardiac and skeletal muscles of lean and obese rats. 
The ratio of Bcl-2 to Bax is indicative of mitochondrial induced apoptotic potential as 
Bcl-2 binds and opposes the pro-apoptotic activity of Bax by preventing Bax conformational 
change or translocation to the mitochondria (8, 18, 31).  Once incorporated into the 
mitochondria Bax is believed to form a pore in the mitochondria membrane that releases 
proteins (e.g. Cytochrome c) which results in a continuation of the apoptotic signaling 
cascade (e.g. Caspase 9 and caspase 3) (2, 26, 29). In this study we observed an increase in 
the Bax to Bcl-2 ratio and an increased Bax protein in the mitochondrial protein fraction of 
the cardiac but not skeletal muscles of the OZR. Furthermore, there was an increase in 
cytochrome c accumulation in the cytosol from cardiac muscles but not skeletal muscles in 
the OZR compared to the LZR.  Additionally, apoptotic signaling downstream of the 
mitochondria including caspase 3 and 9 activities were also elevated in cardiac muscle 
samples of the OZR compared to the LZR. This shows that mitochondrial permeability was 
increased in the cardiac cells of OZR, and that apoptotic signaling was elevated in the cardiac 
muscles samples as well.  Together,  these data may partially explain the increase 
susceptibility to ischemia-reperfusion injury as the cardiac muscle is more prone to apoptosis 
with metabolic syndrome (5, 13). 
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Exercise improves apoptotic signaling in the myocardium of lean and obese rats. 
The second part of this study was to determine the impact that 9-weeks of treadmill 
exercise would have on the Bax to Bcl-2 ratio and associated apoptotic signaling. The 
influence of exercise training on apoptosis has not been fully examined, and only a few 
studies have attempted to define the relationship of acute strenuous exercise with apoptosis in 
skeletal muscle (19, 20). Siu and colleagues (24) found reduced DNA fragmentation in 
ventricle and soleus samples of trained animals when compared to control animals. 
Furthermore, both mRNA and protein contents of Bcl-2 increased in both soleus and 
ventricle muscles of endurance trained animals when compared with control animals.  
However, Bax mRNA levels decreased in the soleus of exercise trained animals when 
compared with control animals. In the present study we observed a tread towards a decreased 
Bax to Bcl-2 ratio (p=0.072) with 9-weeks of treadmill exercise in the cardiac muscle 
samples of the OZR. In addition we observed a significant decrease in the amount of Bax in 
the mitochondrial protein fraction (~50% reduction) of the cardiac muscle samples of the 
OZR after exercise training.   Furthermore, we observed a reduction in both caspase 9 and 3 
activities in the myocardium of the OZR with 9-weeks of treadmill exercise.  Together, these 
data indicate that aerobic exercise prevents mitochondrial apoptotic signaling in cardiac 
muscles of OZR. 
Additionally, we have found that the Bax/Bcl-2 ratio was similar in LZR and OZR 
skeletal muscle samples and exercise did not improve this ratio. These data suggest that 
metabolic syndrome may have a different effect in skeletal verses cardiac muscles.  
Furthermore, these data suggest that skeletal muscle is more resistance to exercise-induced 
improvements in apoptotic signaling than cardiac muscle.  We cannot rule out the possibility 
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that more intense or longer exercise training parameters may have improved apoptotic 
signaling in skeletal muscles of the LZR or the OZR animals.  Previous training studies in 
our lab were performed with a treadmill speed of 28 m/minute, compared to 24 for the LZR 
and 20 for the OZR (the OZR would not comply with faster pace). Nevertheless, the exercise 
parameters in this study were sufficient to induce improvements in citrate synthase activity 
(12), and mitochondrial protein (Cytochrome c Oxidase, unpublished). 
Sandri and colleagues investigated the influence of acute intense exercise on 
apoptosis in skeletal muscles of both young normal and dystrophin-deficient (mdx) mice 
(20). They found that the DNA double strand breaks (as an indicator of DNA fragmentation) 
measured by in situ terminal deoxynucleotidyl transferase-mediated nick end labeling 
(TUNEL) increased by ~20%, 48 h after a night of spontaneous wheel running in both 
normal and mdx mice skeletal muscles. Using DNA gel electrophoresis, they reported that 
the amount of fragmented chromosomal DNA was greater in the skeletal muscles from mdx 
mice after the 16 h spontaneous wheel running when compared with their non-exercise 
partners. The same laboratory reported that TUNEL-positive myonuclei existed after 16 h of 
spontaneous running in skeletal muscles of both C57B and mdx mice (22). Furthermore, they 
found that Bcl-2 protein levels decreased after spontaneous exercise in muscle of mdx mice. 
Similar results of increased apoptotic nuclei and a decreased ratio of Bcl-2/Bax have also 
been documented in skeletal muscles after a 16 h spontaneous wheel running in normal 
healthy animals (19). Activation of apoptosis in muscle tissue following acute bouts of 
exercise is not fully understood; however, these studies suggest that strenuous exercise may 
induce apoptosis in skeletal locomotion muscles. In our study the animals were trained 
gradually and for 9-weeks.  We did not observe any increased apoptotic signaling with 
exercise in skeletal or cardiac muscles of OZR based on Bax, Bcl-2 or DNA fragmentation 
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data. It is possible that an acute bout of exercise may have altered apoptotic signaling 
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Table 1: Values are means ± SE; n, no. of animals. LZR, lean Zucker rat; EX, exercise; OZR, 
obese Zucker rat. * p<0.05 vs. LZR. 
 
 




Figure 1. Average Bax and Bcl-2 protein expression are shown in the heart, soleus, and 
gastrocnemius muscles of lean (LZR) and obese (OZR) animals. The inserts show 
representative western blots for Bax (A) and Bcl-2 (B) from LZR and OZR rats with or 
without 9 weeks of endurance exercise.  Equal protein loading was confirmed for all samples 
by normalizing optical density to ß-tubulin for the each protein sample.  The gels were 
scanned densitometrically and the area and optical density of each band was determined. 
Data for each protein band were calculated as optical density x band area, normalized to the 
β-tubulin band. (C) The Bax/Bcl-2 ratio is shown for heart, soleus and gastrocnemius muscle 
samples from LZR and OZR rats after 9 weeks of endurance exercise. All data are reported 
as means ±SE. * p<0.05 OZR vs. LZR; ** p<0.05 OZR exercise vs. OZR control.  
 
 
Figure 2. To verify that the increase in Bax-to-Bcl-2 ratio resulted in an increase 
translocation of Bax to the mitochondrial membrane, mitochondria protein was isolated from 
the heart tissue. The data are expressed relative to LZR data for each muscle.  The data show 
that cardiac mitochondrial Bax was greater in the OZR than the LZR but mitochondrial Bax 
was lower in cardiac muscle samples taken from exercise trained (ET) OZR compared to 
sedentary animals. All data are reported as means ±SE. * p<0.05 OZR vs. LZR; ** p<0.05 
OZR exercise vs. OZR control; ** p<0.05 OZR exercise vs. obese and lean control.  
 
Figure 3.  A cytochrome c ELISA was conducted on cardiac muscle samples from control 
and exercise trained (ET) LZR and OZR rats. Protein concentration of the sample was 
determined by the BCA assay. The cytochrome c data are expressed as ng•µl muscle protein-
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1.  All data are reported as means + SE. * p<0.05 OZR vs. LZR; ** p<0.05 OZR exercise vs. 
OZR control; ** p<0.05 OZR exercise vs. obese and lean control. 
 
Figure 4. Caspase 3 and 9 activities were determined on cardiac muscle samples from 
control and exercise trained (ET) LZR and OZR rats.  Activities are expressed relative to 
protein concentration.  All data are reported as mean ±SE. * p<0.05 vs. LZR control; ** 
p<0.05 vs. OZR control. 
 
Figure 5. DNA fragmentation was determined on cardiac muscle samples from control and 
exercise trained (ET) LZR and OZR rats. Optical density of the assay was recorded and 
reported relative to protein concentration.  All data are reported as means ±SE. * p<0.05 vs. 
LZR control; ** p<0.05 vs. OZR control. 
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Figure 3: Cytochrome c 
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Denervation procedure  
Hindlimb denervation was performed on a separate cohort of animals as routinely performed 
in our lab (1, 23).  Briefly, the animals were placed under a general anesthesia using 2% 
isoflourene, and after cessation of reflex activity, the tibial nerve was dissected proximal to 
the cranial border of the gastrocnemius muscle. Care was taken to avoid any damage to the 
nerves, blood vessels and connective tissues. The medial and lateral branches of the tibial 
nerve that innervate the plantar flexor muscles (i.e. gastrocnemius and soleus) were cut, and 
the cut nerve ends were sutured into the biceps femoris muscle to ensure that the nerve 
stumps did not reinnervate the gastrocnemius muscle. Innervation to the plantaris and the 
deep toe flexor muscles were left intact so that the animals ambulated normally around the 
cage after the surgical denervation. Following the surgery, the hamstring muscle layers were 
closed with reabsorbable suture, and the skin incisions were closed with wound clips. The 
incision sites were covered with an antibacterial cream to prevent infection. The contralateral 
limb served as the intra-animal control. We have observed that the animals recovered quickly 
and were able to walk around within 45 min post surgery (1).   Withdrawal of innervation to  
the medial gastrocnemius results in an highly-favorable apoptotic environment for this 
muscle (23). 
Muscles examined. 
Muscles from Control and exercise-trained animals were harvested after anesthetizing the 
animals with 2% isoflourene and then euthanized by decapitation. The medial gastrocnemius 
and soleus muscles from each limb were dissected from the surrounding connective tissues, 
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and 4–5 mm of the apex cordis from the heart was quickly removed and frozen immediately 
in liquid nitrogen and stored at –80°C until further analysis. 
 In the second cohort of animals the gastrocnemius muscles was collect seven days 
after the surgical denervation, animals were anaesthetized using 2% isoflourene and the 
animals were then euthanized by decapitation.  The gastrocnemius muscles from each limb 
were dissected from the surrounding connective tissues, removed, and stored at –80°C. 






Denervated Gastrocnemius Muscle.  As neither obesity nor exercise training altered the 
Bax or Bcl-2 content in the skeletal muscle an additional cohort of animals was added in 
which the gastrocnemius muscle was denervated to induce an apoptotic response (1).  Seven 
days of denervation resulted in a ~30% increase in the Bax protein content in the 
gastrocnemius muscle of both the LZR and OZR.  There was also a non-significant increase 
the Bcl-2 content in both phenotypes which resulted in denervation demonstrating no 
increase in the Bax to Bcl-2 ratio (figure S1). 
 
Caspase activity.  To confirm the significance of increase Bax to Bcl-2 ratio in downstream 
mitochondrial apoptotic signaling caspase 3 and caspase 9 activities were examined. In the 
denervated gastrocnemius muscles there was a significant elevation of both caspase 3 and 
caspase 9 activities compared to the intra-animal control. Similar to the Bax and Bcl-2 
protein data there was no difference in the extent of these changes between the LZR and 
OZR. 
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Cell Death ELISA. To determine whether the observed changes in apoptotic signaling 
resulted in cell death, DNA fragmentation was quantified in the cardiac and denervated 
gastrocnemius muscles.  With denervation there was a significant increase (~1.5 fold) in 
DNA fragmentation for both the LZR and OZR compared to the intra-animal control limb.  
However, in agreement with the Bax and Bcl-2 data, there was no difference in the 





It was rationalized that in young adult OZR the effects of obesity may not sufficient 
to reveal differences in apoptotic signaling between the LZR and OZR.  However, if 
apoptosis was induced in skeletal muscle we expected that the OZR would have a magnified 
apoptotic signaling response compared to LZR. To induce skeletal muscle apoptosis we 
denervated the rat gastrocnemius because we have previously shown that this approach  
induces  apoptosis (1).  However, although denervation resulted in nuclear apoptosis in this 
experiment, there was no difference in the magnitude of change between the intra-animal 
controls of the LZR verses the OZR. Contrary to our hypotheses, these data suggest that 










Figure S-1. Representative western blots for Bax and Bcl-2 (A) in denervated and control 
gastrocnemius muscles from LZR and OZR are shown in the figure insert.  Equal loading 
was confirmed for all samples by normalizing optical density to ß-tublin for the each protein 
sample.  The gels were scanned denistometrically and the area and optical density of each 
band was determined. Data for each protein band were calculated as optical density x band 
area, normalized to the β-tubulin band. The Bax/Bcl-2 ratio denervated and control 
gastrocnemius muscles from LZR and OZR (B). All data are reported as means + SE. * 
p<0.05 OZR vs. LZR.  
Figure S-2. Caspase 3 and 9 activities were determined in control and denervated 
gastrocnemius muscles of LZR and OZR. Activities are expressed relative to protein 
concentration.  All data are reported as means ±SE. * p<0.05 vs. LZR control, ** p<0.05 vs. 
OZR control. 
Figure S-3. DNA fragmentation was determined in control and denervated gastrocnemius 
muscles of a second cohort of LZR and OZR. Optical density of the assay was recorded and 
reported relative to protein concentration.  All data are reported as means ±SE. * p<0.05 vs 
LZR control, ** p<0.05 vs. OZR control. 
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Findings and Conclusions from this project 
The studies in this dissertation examine the contribution of satellite cell activation, 
differentiation, and myonuclear apoptosis for maintenance of the myonuclear domain and 
skeletal muscle hypertrophy in models of metabolic syndrome and obesity. The primary finding 
was that there was a significant decrease in proliferation and differentiation of C2C12 myoblasts, 
an in vitro model of satellite cells, when the cells were incubated with palmitate, a primary lipid 
that is upregulated in obesity and the metabolic syndrome.  Furthermore, there was also a 
significant decrease in satellite cell activation in control muscles of the OZR compared with the 
LZR.  The decreased proliferation and differentiation, in vitro, and the decreased satellite cell 
activation, in vivo, corresponded to attenuated Akt signaling in both models of obesity and the 
metabolic syndrome.  It is possible that the decreased Akt protein expression in these models 
accounts for the attenuation of myoblast/satellite cell activation and differentiation.  In support of 
this hypothesis, Akt protein expression increased in response to compensatory loading, and there 
was no difference in the amount of satellite cell activation in loaded muscles of the OZR 
compared with the LZR.  It is likely that the increased load placed on the plantaris muscle by 
denervation of its synergists was sufficient to induce an increase in Akt protein expression in the 
OZR (17, 18), and the enhanced Akt protein expression was sufficient for the increase in satellite 
cell activation in the OZR.  
 
Role of palmitate in regulation of myoblasts and myonuclei 
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The data presented in this dissertation clearly show that palmitate treatment has the 
capability to induce apoptosis in C2C12 myotubes. Furthermore, Akt activity is inhibited by 
palmitate in C2C12 cells and this is consistent with observations in other studies (3, 4).  
However, an apoptotic stimulatory role for palmitate in muscles of animals with metabolic 
syndrome does not appear to be important in vivo. Although Akt activity was reduced in the 
skeletal muscles of the OZR compared to the LZR, there was no increased incidence of apoptosis 
or apoptotic signaling.  The absence of apoptotic signaling in the skeletal muscles of the OZR 
was surprising. However, in addition to increased circulating levels of fatty acids, the OZR have 
a variety of other factors that may have acted to protect the skeletal muscle from the negative 
effects of palmitate.  One example of this is the elevated UCP3 protein expression observed in 
the OZR compared to the LZR (see supplemental data).  UCP3 is believed to protect the 
mitochondria from free fatty acid-induced damage (12, 20). Comparatively, in our hands 
palmitate-treated myotubes showed no increase in UCP3 protein expression.  Another 
explanation for the possible lack of apoptosis in the skeletal muscles of the OZR could be the 
fact that although the OZR have elevated palmitate levels, there is also an increase in the amount 
of unsaturated free fatty acids as well.  It has been proposed that unsaturated free fatty acids may 
have a protective role and help stabilize and/or slow down the metabolism of saturated free fatty 
acids (22). 
 
CHAPTER 6   Peterson 149 
 
Limitation and Future Directions 
The rationale for this project was that reduced skeletal muscle mass with metabolic 
syndrome would be detrimental, because skeletal muscles are the primary tissue in regards to 
glucose and fatty acid oxidation (1, 2, 16). Disruptions of either glucose or fatty acid oxidation 
are major contributors to complications associated with obesity and the metabolic syndrome. 
Understanding the mechanism in which obesity and the metabolic syndrome may inhibit skeletal 
muscle growth may lead to treatment options aimed at improving skeletal muscle growth and 
hypertrophy. 
The design of this study specifically focused on examining the mechanism to explain the 
smaller skeletal muscles in the OZR compared to the LZR. This study design also examined the 
effects of the saturated free fatty acid palmitate on myoblasts (an in vitro model of satellite cells) 
and myotubes (an in vitro model of mature skeletal muscle).  Palmitate was selected because the 
OZR have a significantly higher plasma and intramuscular concentration of palmitate compared 
to the LZR (13, 21).  Furthermore, palmitate has been previously shown to be sufficient to inhibit 
Akt activity due to it’s metabolite ceramide (3, 4).   
Although the selection of palmitate in vitro was appropriate for this study, it also 
accounts for one limitation of this study design.  High palmitate levels are not the only difference 
between the OZR and LZR.  Future in vitro studies should focus on other aspects of metabolic 
syndrome besides higher palmitate levels.  For example, non-saturated free fatty acids, which are 
also elevated in the OZR, have different metabolites and have been demonstrated to stabilize the 
saturated fatty acids and may protect the cells from apoptosis (4, 10, 11, 19). To test this 
hypothesis the monounsaturated fatty acid oleate would be added to the media to determine 
whether it protects the myotubes from apoptotic signaling induced by palmitate. The co-
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incubation of oleate with palmitate has been previously demonstrated to reverse palmitate-
induced insulin resistance and inflammation in skeletal muscle cells (7). The research design for 
testing the effects that oleate would have on reversing palmitate mediated apoptotic signaling in 
C2C12 myotubes would be performed in five groups as follows: (i) Palmitate only (0.075 mM), 
(ii) Palmitate and Oelate (0.75 mM of each), (iii) Palmitate and Oelate (0.375 mM of each), (iv) 
Oleate only (0.75 mM), and (v) Laurate (0.75 mM).  
The findings of this study demonstrated that elevated palmitate was sufficient to inhibit 
skeletal muscle proliferation and differentiation, at least in vitro. However, besides increased 
palmitate levels, the OZR also has increased levels of adipokines, particularly leptin.  To 
determine whether these additional adipokines, (i.e. Leptin) also interfere with myoblast 
proliferation and differentiation this study design will be repeated with the addition of adipokines 
to the cells and their influence on proliferation and differentiation would be determined.  
Together, understanding the affects of these adipokines may be beneficial for understanding 
additional mechanism in which obesity and the metabolic syndrome may interfere with skeletal 
muscle growth and hypterophy. 
Although the OZR is a well established genetic model of obesity and metabolic 
syndrome, follow-up studies using diet induced obesity could be performed.  Briefly, animals 
would be divided into a normal chow diet (10% calories from fat) compared to high-fat diet 
(60% calories from fat and fed ad libitum for 9 weeks, as performed by others previously (5, 8, 
23).  After nine-weeks of feeding, the BrdU implantation procedure preformed in this study 
would be repeated in these animals.  
Although satellite cell activation was reduced in the unloaded skeletal muscles of the 
OZR compared to the LZR, we were able to induce significant satellite cell activation with 
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compensatory loading.  This highlights another limitation of the present study as compensatory 
loading is a physiological, but severe, loading model that would be unrepeatable in translationa 
research. This was the first study to demonstrate hypertrophy in a rat model of obesity and the 
metabolic syndrome, and demonstrates that hypertrophy and satellite cell activation is possible. 
However, future work needs to be done to determine if less severe models of loading could also 
restore satellite cell activation.  For example, Cutlip et al. have develop a chronic exposure to 
stretch-shortening contractions model in rats using a dynamometer for testing mal-adaptation in 
young verse old rats (9). This model could be used in OZR, or in high-fat fed rats, to test for mal-
adaptation or satellite cell activation (through BrdU incorporation). 
It would be important to discover if there is a decrease in the satellite cell activation in 
young developing adolescents. The results of the National Health and Nutrition Examination 
Survey 2003-2004 indicate that the prevalence of obesity is increasing, especially in young 
people, effecting approximately 17% of Americans 2-19 years of age (6, 14, 15). With increased 
obesity there is an elevation of lipids in the circulation, similar to that observed in the OZR.  It 
would be important to discover if there is a decrease in the satellite cell activation in young 
developing adolescents and to discover if this could be restored with loading (resistance 
training).  These data may provide important information in developing treatment strategies for 
obese adolescents and alter the way in which obesity and the metabolic syndrome is managed. 
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Running title: Obese Zucker rats and UCP3 




Uncoupling protein 3 (UCP3) is a mitochondrial inner membrane protein which is thought to shuttle non-
metabolize fatty acids, particularly when there are excessive fatty acids present. PURPOSE: Obese 
zucker rats (OZR) have systematically elevated levels of fatty acids, with decrease fatty acid metabolism. 
We hypothesized that basal UCP3 protein expression levels would be elevated in the skeletal muscles of 
the OZR compared to the lean zucker rats (LZR). In addition, because aerobic exercise training has been 
shown to elevate the ability of skeletal muscle to metabolize lipids, we also hypothesized that aerobic 
exercise training would decreased UCP3 protein expression in the skeletal muscles, and that this decrease 
would be more pronounced in the skeletal muscles of the OZR. METHODS: OZR and LZR animals 
were aerobically trained on a motorized treadmill for 55 minutes a day 5 days per week for 9 weeks. 
UCP3 and oxidative enzymes were measured in the plantaris, gastrocnemius, and soleus muscles of the 
animals. RESULTS: Basal UCP3 protein expression was found to be elevated 8-fold in the plantaris 
muscles and 3-fold in the gastrocnemius muscles of the OZR compared to the LZR (p < 0.05). However, 
there was no difference in UCP3 protein expression in the soleus muscles of the OZR compared to the 
LZR (p = 0.34). Furthermore, aerobic exercise training did not significantly alter UCP3 protein 
expression in the soleus, plantaris, or gastrocnemius muscles of the LZR; however UCP3 protein 
expression levels decreased in the trained soleus and gastrocnemius muscles compared with controls. 
CONCLUSIONS: The decrease in UCP3 with aerobic exercise training was most notable in the soleus of 
the OZR. These data demonstrate that there are muscle specific effects of obesity and aerobic exercise 
training on UCP3 protein expression levels. 
 
Key words: CITRATE SYNTHASE, AEROBIC TRAINING, UNCOUPLING PROTEIN 3, 
METABOLIC SYNDROME 





Paragraph number 1. Uncoupling proteins are a family of mitochondrial inner membrane proteins, 
which are believed to be involved in the regulation of energy expenditure. Uncoupling protein 1 (UCP1), 
which is highly expressed in brown adipose tissue, has been clearly demonstrated to contribute to 
thermogenesis [see reviewed (1).  Uncoupling protein 3 (UCP3) is a member of the uncoupling protein 
family that is highly expressed in skeletal muscle, and shares a ~60 homology to UCP1 (2). Although 
UCP3 was originally believed to have a similar function to UCP1, based on its homology, it has been 
established that UCP3 does not contribute to thermogenics or muscle proton leak [reviewed (3)].  A 
potential function of UCP3 is that UCP3 may serve as a mitochondrial mediator of fatty acid metabolism 
in the muscle It has been demonstrated that elevated circulating free fatty increases muscle UCP3 protein 
expression levels in both in human and animal models (4-7), perhaps as an attempt to prevent lipid-
induced oxidative damage to muscle mitochondria. Furthermore, when free fatty acid levels are elevated 
during exercise there is an increase in UCP3 mRNA (8;9), and protein levels (10;11). On the other hand it 
has been proposed that UCP3 may play a protective role against reactive oxygen species (ROS) 
production (3;12;13), although this may be directly related to preventing lipid peroxidation (3).  
Nevertheless, these data support the hypothesis that UCP3 is actively involved in free fatty acid 
metabolism and therefore, the increase in UCP3 with acute exercise may be a means of mitochondria 
protection under conditions of high fatty acids. 
 
Paragraph number 2. In contrast to an acute bout of exercise, long-term aerobic exercise training may 
produce the opposite effect on UCP3. Boss et al. reported that 8-weeks of treadmill running resulted in a 
76% and 59% decrease in UCP3 mRNA in the tibialis anterior and soleus muscles of rats, respectively 
(14), however, it is not known if the UCP3 protein levels were also decreased in this study. Similarly, in a 
cross-sectional study, the UCP3 protein levels in quadriceps muscles of endurance-trained men were 
SUPPLEMENTAL DATA  Peterson 157 
 
  
significantly lower when compared with untrained controls (15). Furthermore, Fernstrom and colleagues 
(16) demonstrated that long-term aerobic training decreased UCP3 protein expression when normalized to 
mitochondrial activity. Combine these data provide evidence that the increase UCP3 protein expression is 
transient and that the UCP3 contributes to the acute adaptation to exercise (3).  However, to our 
knowledge no study has examined the response of UCP3 protein expression levels to aerobic exercise 
training in primarily glycolytic muscles, like the plantaris, vs. a primarily oxidative muscle like the 
soleus. 
 
Paragraph number 3. In addition to aerobic training, obesity, or any situation in which free fatty 
acid levels were elevated, could alter UCP3 protein expression levels.  For example, in rodent models a 
high fat diet induced an increase in UCP3 protein expression in some (5;6;17), although not all studies 
(18).  For example, Chou and colleagues (6) determined that high fat diet (60% of energy from fat, for 4 
weeks) increased UCP3 content along with plasma free fatty acid levels.   The obese Zucker (fa/fa) rat 
(OZR) is rodent model consistently used in the literature as a model of severe obesity.  The OZR have a 
dysfunctional leptin receptor and therefore do not properly regulate their food intake (19).  This results in 
rapid and severe obesity, skeletal muscle insulin resistance, hyperglycemia, and high levels of free fatty 
acids (20-22). Because of the high levels of plasma free fatty acids in the OZR it would be expected that 
the OZR would have increased UCP3 expression, compared to the lean zucker rat (LZR), similar to the 
high fat feeding model. However, previous work in the OZR has demonstrated that there is a decrease in 
the UCP3 mRNA expression in the soleus muscle compared to the LZR (23) whereas, in a separate study 
there was a significant increase in UCP3 protein expression in the quadriceps of the OZR compared to the 
LZR (20).  However, neither of these studies examined UCP3 expression in multiple types of muscles 
(glycolytic or oxidative muscles). This is important because it is possible that the response of UCP3 to 
treatment (e.g., diet or exercise) could be muscle phenotype specific and vary between glycolytic 
compared to oxidative muscles (4;24-27).  For example, Schrauwen and colleagues (24) demonstrated 
that the regulation of UCP3 protein expression, in response to a high fat diet, was related to muscle fiber 
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type in healthy humans.  Similarly, both glycolytic and oxidative skeletal muscles of the OZR are 
exposed to significantly higher levels of free fatty acids compared to the LZR (28). However, the 
regulation of UCP3 to either the severe obesity, as observed in the OZR, or aerobic exercise could be 
different depending on the muscle being examined. Together, these data demonstrate the need for further 
study of the interaction between obesity, aerobic exercise training, and UCP3 protein expression levels in 
both oxidative and glycolytic skeletal muscles.   
Paragraph number 4. It has been demonstrated that aerobic exercise training increases the proteins 
responsible for fatty acids oxidation (29). Increased metabolism of fatty acids would reduce the need for 
UCP3 to remove non-metabolized fatty acids, which in turn could allow for the decrease in UCP3 protein 
expression in skeletal muscle with aerobic exercise training (3;8;14;30).  However, there is a scarcity of 
data concerning the interactions of obesity, muscle oxidative capacity, and exercise on UCP3 content in 
skeletal muscle. Therefore, the purposes of this study were three-fold: (i) first to determine if basal UCP3 
is elevated in both fast and slow hindlimb muscles of OZR compared to LZR; (ii) secondly, to determine 
whether aerobic exercise alters the content of UCP3 in the skeletal muscles of the OZR differently from 
the LZR; (iii) third, to determine if changes in UCP3 protein expression are dependent on the oxidative 
capacity of the muscle being examined. 
 





Paragraph number 5. Animals.  An equal number of 6 week old male OZR and LZR rats (Harlan, 
Indianapolis, IN) were randomly assigned to control (C, n = 16) or training (ET, n = 16) groups.  Animals 
were housed in pathogen-free conditions, two per cage, at 20-22°C with a reversed 12:12-h light-dark 
cycle, and fed rat chow and water ad libitum throughout the study period.  All animal procedures were 
conducted in accordance with institutional guidelines, and ethical approval was obtained from the Animal 
Care and Use Committee at the West Virginia University.  
 
Paragraph number 6. Training protocol. Animals were trained by running on a level motorized rodent 
treadmill (Columbus Instruments, Columbus, OH) 5 days weekly for 9 weeks. During the first 4 wk, the 
speed of the treadmill and duration of the training sessions were gradually increased from a speed of 
10 m/min for 10 min to a running speed of 20 m/min for the OZR and 24 m/min for the LZR. Different 
speeds were used to compensate for the increased intensity of exercise for the OZR due to increased body 
weight compared to LZR.  Our pilot work suggested that the difference in body weight would vary around 
40% and we used an estimation based on the formula of “work=1/2 mass * velocity squared 
(W=1/2m*V2)” and the estimated final weights of 500 grams for the OZR and 350 grams for the LZR.  
This calculation estimates that at 20 and 24 m/min for the OZR and LZR, respectively, they would have 
an estimated final work output of 0.028 joules. Furthermore, our pilot data demonstrated that these 
intensities would be able to be reliably maintained by the OZR and LZR, respectively, with minimal 
motivation by the investigators. Additionally, as demonstrated by the mitochondrial proteins examined in 
this study we saw similar increases in the trained groups of both the OZR and LZR. During weeks 
5 through 9, a 5-min warm-up session at a speed of 15 m/min was followed by the 55-min training 
session. During the training sessions, mild electrical shock stimulation was applied, if necessary, to 
maintain the running motivation.  Animals assigned to the control group were handled daily and exposed 
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to the noise of the running treadmill by placing their cages next to the treadmill during the exercise 
session. 
 
Paragraph number 7. Forty eight hours after the last training session and an overnight fast (~16 hours) 
animals were anesthetized with isoflurane and euthanized via cardiac puncture at which time the soleus, 
plantaris, and gastrocnemius muscles were quickly removed, frozen immediately in liquid nitrogen and 
stored at -80°C until further analysis. These muscles were chosen to examine changes in UCP3 in 
response to aerobic training in the oxidative (soleus), glycolytic, (plantaris), and mixed oxidative and 
glycolic (gastrocnemius) muscles. Although it has been demonstrated that there is a reduction in percent 
of total fiber area occupied by the glycolytic fibers in the OZR compared to the LZR, the relative 
percentage of the glycolytic to oxidative fibers remained constant (31).  Torgan et al. 
demonstrated that the OZR has ~77% type I fibers in the soleus muscle compared to the LZR 
(~83%), with no difference in fiber type percentages in the plantaris muscle between the OZR 
and LZR (~10% type I, ~68% type IIa, and ~22% IIb). 
 
Paragraph number 8. Western Blot analyses. Protein extracts were obtained from hindlimb muscles as 
routinely performed in our lab (32).  The protein contents of the solublized extracts were quantified in 
duplicate by using bicinchoninic acid reagents (Pierce, Rockford, IL, USA) and bovine serum albumin 
(BSA) standards.  40 µg of soluble protein was boiled for 4 min at 100°C in Laemmli buffer and loaded 
on each lane of a 12% polyacrylamide gel.  The proteins were separated by NuPage Bis-Tris gel 
(NP0303, Invitrogen, CA, USA) with NuPage Running Buffer MES-SDS (NP0002; Invitrogen, CA, 
USA) for 1.5 hours at 20°C, and molecular weight was confirmed with SeeBlue2®Plus2 (LC5925, 
Invitrogen, CA, USA).  The gels were blotted to nitrocellulose membranes (Bio-Rad, Hercules, CA, 
USA) and stained with Ponceau S red (Sigma Chemical Co, St Louis, MO, USA) to confirm equal 
loading and transferring of proteins to the membrane in each lane. 
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 Paragraph number 9. The membranes were then blocked in 4% non-fat milk in Tris buffered 
saline with 0.05% Tween 20 (TBS-T) and probed with an UCP3 antibody (AB3046; Chemicon, CA, 
USA), cytochrome c oxidase subunit I (COX I; Invitrogen, CA, USA) or beta-tubulin antibody (Abcam, 
MA, USA).  Isolated skeletal muscle mitochondrial protein and rat liver homogenate were used as 
positive and negative controls, respectively, for UCP3. Secondary antibodies were conjugated to 
horseradish peroxidase (HRP) (Chemicon) and the signals were developed by chemiluminescence (Pierce, 
Rockford, IL, USA).  The signals were visualized by exposing the membranes to X-ray films (BioMax 
MS-1, Eastman Kodak, Rochester, NY, USA), and digital records of the films were captured with a 
Kodak 290 camera.  The resulting bands were quantified as optical density (OD) x band area by a one-
dimensional (1-D) image analysis system (Eastman Kodak, Rochester, NY, USA) and expressed in 
arbitrary units normalized to the OD of beta-tubulin.  The sizes of the proteins were verified by using 
standard molecular-weight markers (Bio-Rad, Hercules, CA, USA).   
 
Paragraph number 10. Citrate synthase activity assay.  Approximately 20 mg of soleus muscle samples 
were homogenized on ice in 0.1 M Tris buffer containing 0.1% Triton X-100, pH 8.35.  Citrate synthase 
(CS) activity was determined spectrophotometrically according to the method of Srere et al (33) and as 
conducted routinely in our laboratory.  The homogenates were frozen under liquid nitrogen and thawed 
four times to disrupt the mitochondria in order to release the CS.  The assay system was in a total volume 
of 200 µl: 100 mM Tris buffer (pH 8.35), 5 mM 5,5-dithiobis (2-nitrobenzoate) (DTNB), 22.5 mM acetyl-
CoA, 25 mM oxaloacetate (OAA), and 4 μl of homogenate.  The rate in change in color was monitored at 
a wavelength of 405 nm sec intervals for a period of 3 min by using a Dynex MRX plate reader controlled 
through PC software (revelation, Dynatech Laboratories, CA, USA).  All measurements were performed 
in duplicate, in the same setting at 20-22°C.  The solublized protein extracts of the homogenates were 
quantified in duplicate by using bicinchoninic acid reagents (Pierce, Rockford, IL, USA) and BSA 
standards.  The CS activity was normalized to the total protein expression and was reported as nanomoles 
per milligram protein per minute. 




Paragraph number 11. Statistical analyses.  Results are presented as means ± SE. A One-way ANOVA 
was used to examine differences across groups. Tukey's Post hoc tests were used to determine differences 
between the means. Significance was set at P < 0.05. 





Paragraph number 12. Characterization of animals.  At the start of this study the OZR had significantly 
elevated body weights compared to the LZR (224.6 ± 16.6 vs. 171.9 ± 14.9 g, p < 0.05).  No differences 
in starting body weight were observed between control and trained animals within phenotype.  After 
training, the animals were 15-16 weeks old.  Training significantly lowered the body weights of OZR 
(658 ± 18 vs. 502 ±21 g, p < 0.05) but not LZR (358 ± 11 vs. 360 ±16 g)  animals as previously reported 
(22). 
 
Paragraph number 13.  UCP3 protein levels.  The effects of obesity and/or exercise on the protein 
concentrations of UCP3 in the hindlimb muscles were dependent on the muscle being examined.  In the 
fast contracting plantaris and medial gastrocnemius muscles, there was an 8-fold and 3-fold increase, 
respectively, in the basal level of UCP3 in the OZR compared to the LZR (Figure 1A & 1B).  However, 
this difference was not observed in the soleus muscles of the OZR compared to the LZR (Figure 1C). 
Exercise had no effect on UCP3 concentration in either the fast contracting plantaris or medial 
gastrocnemius muscles (Figure 1A & 1B).  Additionally, aerobic exercise had no effect on the UCP3 
content in the slow contracting soleus muscles of the LZR.  Conversely, in the soleus muscles of the OZR 
there was a 67% decrease with aerobic exercise (Figure 1C). 
 
Paragraph number 14.  COX I protein levels.  COX I is an inner mitochondrial membrane–
bound enzyme which has a role in the electron transport chain.  COX I was examined as a marker for 
mitochondrial content (11). This measure was important to determine if the training protocol was 
effective in increasing the mitochondrial protein fraction, and secondly to help determine whether 
changes in UCP3 expression were consistent with or independent from mitochondrial biogenesis.  COX I 
protein expression increased in both the plantaris and soleus muscles with training (Figure 2A).  
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Furthermore, UCP3 normalized to COX I protein expression (UCP3/COX I) was also examined (Figure 
2B).  UCP3/COX I was reduced in both the medial gastrocnemius (42%) and the soleus (59%) muscles of 
the LZR animals, but there was no change in the plantaris muscles.  In the OZR, UCP3/COX I was 
reduced in the plantaris and soleus muscles, by 30% and 81% respectively, with no change in the medial 
gastrocnemius muscles. 
 
Paragraph number 15.  Citrate Synthase activity. To further verify that the training protocol was 
effective, CS activity, shown in figure 3, was measured biochemically in the soleus muscles of all trained 
and control animals.  Similarly, to past studies from our lab (32), CS activities increased by ~30% in 










Paragraph number 16. The primary novel findings from this study are that UCP3 protein 
expression is affected by obesity and muscle phenotype, in the OZR. In this study we show a significantly 
greater basal UCP3 protein expression in the fast contracting glycolytic muscles of the hindlimb 
(gastrocnemius and plantaris) of the OZR compared to the LZR; however, there was no affect of obesity 
on UCP3 protein expression in the slow contracting oxidative soleus muscles.  
 
Paragraph number 17. Previous research has shown that the OZR has significantly elevated palmitate 
(the most common free fatty acids found in the body) uptake per gram of muscle tissue as compared with 
LZR (28). This increase in exposure to free fatty acids may partially explain the increased UCP3 protein 
expression in the plantaris and gastrocnemius muscles that we observed in the current study.  However, it 
remains unclear why UCP3 protein expression is not different in the soleus muscles of the LZR and the 
OZR.  One possible explanation is that UCP3 expression may be determined in part by the manner in 
which fatty acids are stored in glycolytic and aerobic muscles.  For example, Turcotte and colleagues (28) 
reported that glycolytic muscles in the OZR have elevated diacylglycerol synthesis compared to the LZR, 
whereas the oxidative muscle have elevated triglyceride synthesis compared to the LZR.  However, the 
interactions between UCP3 and di- or triglycerides have not been elucidated.   Another possibility is that 
the mitochondria in highly oxidative soleus muscles have sufficient UCP3 to provide stabilization to the 
mitochondria under conditions of high fatty acids, whereas, mitochondria in fast contacting muscles have 
less UCP3 and respond to the exposure of fatty acids by elevating the expression of UCP3. 
 
Paragraph number 18. In this study we report that 9 weeks of aerobic exercise training resulted in 
decreases in UCP3 protein expression, and UCP3 expression normalized to mitochondrial protein 
expression, in the hindlimb muscles.  It is important to note that nine weeks of aerobic training at 
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this intensity and duration were sufficient to increase the mitochondrial protein expression (COX I) in the 
plantaris and soleus muscles of both the LZR and OZR, and that these increases were not different 
between groups. This would indicate that the animals had achieved adaptations to the aerobic exercise, 
and that the different training speeds were appropriate to illicit similar increases in mitochondrial protein 
expression in both the LZR and OZR. Furthermore, the soleus muscles of both the LZR and the OZR had 
significant increases in mitochondrial protein (COX I) and mitochondrial activity (CS activity) with a 
relative decrease in UCP3 protein expression. It has been proposed that aerobic training increases 
metabolic efficiency, which decreases the expression of UCP3 in skeletal muscle (14;34;35) perhaps 
because mitochondria are stabilized to prevent oxidative damage by elevation of other oxidative enzymes 
(e.g., MnSOD, GPx, GSH/GSSG) in muscle or blood (36-38). Recent data provide additional evidence 
that UCP3 may provide a protective role for mitochondria, because the enhanced H2O2 emitting potential 
of mitochondria is returned to resting levels when UCP3 is increased in vivo (39). Furthermore, Hellsten 
and colleagues (40) have recently shown that antioxidant supplementation increased UCP3 expression 
levels in muscle after acute exercise and this suggests a clear linkage of UCP3 and adaptations to 
oxidative stress. In addition, to regulation by oxidative stress, the decrease in UCP3 levels after aerobic 
training in the current study could also be indicative of adaptations in muscle mitochondria to exercise 
because UCP3 contributes to the rate of state 4 respiration in skeletal muscle mitochondria (41). In 
support of this hypothesis, other studies which have examined chronic aerobic exercise training models, 
have also demonstrated a decrease in UCP3 expression with training (14;15).  
 
Paragraph number 19. Our findings, are in agreement with data from previous studies which found that 
protein expression of UCP3 does not increase in parallel with training-induced mitochondrial biogenesis 
(14;16;42).  However this is contrary to the findings of others who reported increased UCP3 protein 
concentration (11) or mRNA expression (11;35) during 10 or 14 days, respectively, of aerobic training.  
We cannot rule out the possibility that there was an initial increase in UCP3 protein levels during the first 
2-weeks of exercise training, but if this occurred, then this was a transient increase.  This possibility, 
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would explain why Jones and colleagues (11) found a parallel increase in UCP3 concentration and 
mitochondrial biogenesis.  Our data suggest that such acute increases in UCP3 would likely be transient, 
since decreased UCP3 protein concentration and mRNA expression are reported both with aerobic 
training (14;16) and in aerobic trained cross-sectional studies (4;15;42).  It is possible that if UCP3 
protein concentration was examined within 24 hours of the last training bout an increased protein 
concentration would have been observed as in aforementioned studies.   
 
Paragraph number 20.  A novel finding of this study was that the reduction in UCP3 protein 
expression with aerobic exercise training was more evident in the soleus muscle of the OZR than in the 
soleus of the LZR, or in either of the glycolytic muscles.  It has been demonstrated that muscles higher in 
type I fibers (like the soleus) are more susceptible to exercise induced changes in UCP3 content (27).  
This may partially explain why the soleus muscles, which is composed of ~80% type I fibers (43;44), 
demonstrated the most notable decline in UCP3 protein expression.  Although there are significant 
differences in skeletal muscle fiber type percentages in  muscles of the OZR compared to the LZR, the 
general trend in fiber type distribution remains similar to other rodent models, with the soleus muscle 
being composed primarily of type I fibers (~80%), the plantaris with predominately type IIa fibers 
(~60%), and the gastrocnemius representing both type I and type II fibers  (29;43;44).  Furthermore, it 
was confirmed in this study that among the muscles examined UCP3 protein expression followed a 
similar pattern in the OZR and LZR with it being lowest in the soleus muscles and no difference between 
the plantaris and gastrocnemius muscles.  
 
Paragraph number 21. OZR animals were heavier than LZR animals, so if the animals were to 
run at the same pace, the muscles of the OZR animals would have a greater total workload than the LZR. 
Although we attempted to match training intensities by allowing the LZR to run at a faster pace than the 
OZR, we cannot completely rule out the possibility that potential differences in the training intensity may 
explain, at least in part, why the changes in normalized UCP3 protein expression were different between 
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phenotypes.  Nevertheless, it is apparent that both animal phenotypes increased mitochondrial protein 
expression in the plantaris and soleus muscles similarly, but that decreases in normalized UCP3 protein 
expression were more pronounced in the OZR. 
 
Paragraph number 22. In conclusion, this study demonstrated that there is an interaction effect 
of muscle type (glycolytic or aerobic) and obesity in regards to the effect on UCP3 protein expression.  
Although the OZR has a significantly elevated UCP3 protein expression in the glycolytic muscles 
(plantaris) there was no difference in the aerobic muscles (soleus) between the two animal groups.  On the 
other hand, aerobic exercise had a similar effect on lowering the protein expression of UCP3 relative to 
the mitochondrial protein COX I.  These data indicate that although there are differences in between the 
LZR and OZR, aerobic exercise affects them similarly.   
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Figure 1 UCP3 content in hindlimb muscles. The UCP3 protein expression was examined by 
Western immunoblots in the plantaris (A), medial gastrocnemius (B), and soleus muscles 
(C). Male obese Zucker (OZR-ET), n=8) and lean Zucker (LZR-ET, n=8) were 
endurance trained (ET) on a motorized treadmill for 12 weeks. Control (LZR, n = 8; 
OZR, n=8) LZR and OZR animals were exposed to the similar environment (positioned 
next to the treadmill) but were not exercised.  The insets show representative Western 
blots for UCP3 and β-tubulin.  β-tubulin was used as the loading control for each sample. 
The data are expressed in arbitrary units with UCP3 normalized to the β-tubulin content 
of each lane, and presented as means ± SE. *P < 0.05, data from OZR animals was 
significant different from the LZR animals. **P < 0.05, significantly different from all 
other groups.  The main effects of obesity (OZR or LZR) and exercise interaction 
(obesity x exercise) in these animals were analyzed by a 2 × 2 ANOVA. Data are 
presented as means ± SE.  
 
Figure 2 The effects of endurance training on COX I protein expression. (A) The COX I 
protein expression was examined by immunoblot analysis. We recorded a band at ~37 
kDa as known in previous studies (45).  The insets show representative Western blots for 
COX I and β-tubulin, which was used as the loading control for each sample. The data 
are expressed in arbitrary units with COX I normalized to the β-tubulin content of each 
lane.  (B) UCP3 protein expression normalized to COX I protein expression. Data are 
presented as means ± SE. *P < 0.05, data significantly different from the LZR control 
animals. **P < 0.05, significantly different from control OZR. The main effects of 
obesity (OZR or LZR) and exercise interaction (obesity x exercise) in these animals were 
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analyzed by a 2 × 2 ANOVA. Data are presented as means ± SE. Other abbreviations are 
identical to Figure 1. 
  
Figure 3 The effects of endurance training on citrate synthase (CS) activity in soleus muscles. 
CS activity was determined in the soleus muscle of control and aerobically trained LZR 
and OZR rats. CS activity is normalized to the total protein expression of the sample used 
in the assay. Data are normalized to the protein expression of the sample and expressed as  
   units • mg prot-1 • min-1. *P < 0.05, data significantly different from the LZR control 
animals. **P < 0.05, significantly different from control OZR.  Data are presented as 
means ± SE. Other abbreviations are identical to Figure 1. 
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IN VITRO METHODS 
C2C12 Culture.   
C2C12 myoblasts were purchased from American Type Culture Collection (ATCC, 
Manassas, VA).  The cells were cultured in 100 mm polystyrene culture dishes in Dulbecco 
Modified Eagle’s Medium (Invitrogen, USA) supplemented with 10% FBS and 1% antibiotic 
antimycotic mixture and passaged in 0.25% trypsin. The cells were maintained in a humidified 
incubator under an atmosphere of 5% CO2 at 37ºC.  Fresh medium was supplied every 24-36 
hours unless otherwise noted.  
Differentiation.   
For differentiation into myotubes, the myoblasts were grown to confluency and transferred to 
DMEM containing ITS liquid media (Sigma-Aldrich, St. Louis, MO).  Myotubes were used for 
experiments following 4 days of differentiation, unless otherwise noted.  All experiments were 
performed in triplicate. 
Free Fatty Acid Treatment.  
Palmitate (Sigma Chemicals; St. Louis, MO) was administered to cells as described by Chavez 
and Summers (46;47) with dodecanoic acid (laurate) used as a short chain free fatty acid (FFA) 
to differentiate the effects of  FFAs alone and FFAs which interfere with Akt signaling. Briefly, 
palmitate was dissolved in ethanol and diluted in DMEM containing 2% BSA. C2C12 myotubes 
were incubated with the FFAs (0.75mM final concentration) in 1% FBS–DMEM for 16 h, 
washed with DHANKS, and then incubated with the FFA in serum free DMEM for 2 hours.  1% 
FBS was reintroduced to the media 10 minutes prior to collection, except where indicated. 
C2C12 myoblast were incubated with FFAs (0.25mM final concentration) in 10% FBS for 12-24 
hours and harvested immediately, except where indicated. Control experiments were performed 
with 2% BSA in the absence of FFAs. 
Myoblast proliferation.  
The first experiment performed was to determine if palmitate treatment inhibited myoblast 
proliferation.  For this experiment C2C12 myoblasts were suspended in trypsin, centrifuged at 
20ºC for 5 minutes at 1500 rpm and then resuspended in PBS. Next 10 µM carboxyfluorescein 
diacetate, succinimidyl ester (CFSE) was added to the cells and then the staining was 
immediately quenched with the addition of an equal volume of 10% FBS.  An aliquot was fixed 
in 1% paraformaldehyde, to determine initial staining intensity. The cells were then plated into 
35mm plates in 10% FBS and allowed to grow for 24 hours.  At this point the myoblasts were 
treated with palmitate, laurate, Akt-inhibitor (124005, Calbiochem, Germany) or BSA only and 
allowed to grow for an additional 24 hours.  Next, the myoblasts were washed twice with PBS, 
harvested in 0.25% trypsin, and fixed with 1% paraformaldehyde, and examined using the 
FACSCaliburTM Flow Cytometer. 
An additional proliferation assay was performed in a separated experiment in which the 
C2C12 myoblasts were grown to ~50 percent confluency, treated with or without FFAs, pulsed 




for 20 min with 30 µg/ml BrdU (550891, BD Biosciences Pharmingen, USA), harvested in 
trypsin, and fixed in ice cold 70% EOTH for 24 hours.  The myoblast were then resuspended in 
0.1% triton-X/0.1 M HCL for 1 min, centrifuged at 2000 rpm for 5 min, then resuspended  in 
DNA Denaturing Buffer (0.15 µM NaCl, 15 µM Trissodium citrate dihydrate) at 95°C for 5 min, 
followed by incubation at 4ºC for 5 min, and centrifuged 2000 rpm 5 min.  Next the pellet was 
washed in 1% BSA in PBS and then resuspended in Mouse anti-BrdU (1:50; 555627; BD 
Pharmingen™, USA) for 30 min at room temperature.  Next the cell were washed twice in PBS 
and then incubated with Anti-mouse Alexa-488 secondary antibody (1:400; A11029; Invitrogen, 
USA).  Lastly, the myoblasts were wash twice with PBS and then resuspended in Propidium 
Iodide (10 µg/ml; P3566, Invitrogen, USA), RNAse (100 µg/ml; 10109169001; Roche, USA) in 
PBS and analyzed a FACSCaliburTM Flow Cytometer. 
Flow Cytometry Analysis.  
The cells were transferred to 5 ml polstytrene round bottom tubes for data acquisition and 
analysis on a FACSCaliburTM Flow Cytometer using CellQuest Pro software (BD Biosciences).  
All data are represented as mean fluorescence intensity (MFI). Additional cell cycle modeling 
was performed using Modfit LT software (Verity Software house, Inc). 
siRNA transfection.   
The myotubes were transfected with scrambled, nonspecific siRNA without mammalian 
homology, or Bax siRNA (Santa Cruz Biotechnology, Santa Cruz, CA) using Lipofectamine 
2000 (Invitrogen Carlsbad, CA).  Individual siRNAs (80 pmols/transfection) were transfected 
using Lipofectamine in serum-free DMEM for 6 hours.  A 2x concentration (2%FBS, 4% BSA, 
and 1.25 mM of palmitate) of media was then added to each well and the samples were incubated 
for an additional 12 hours.   
 
 





IN VIVO MODELS 
Animal Care.  
Obese and Lean zucker rats were purchased from Harlan labs (Harlan, Indianapolis, IN).  
Animals were housed in pathogen-free conditions, at 20-22°C, and fed rat chow and water ad 
libitum throughout the study period. The animal care standards were followed by adhering to the 
recommendations for the care of laboratory animals, as advocated by the American Association 
for Accreditation of Laboratory Animal Care, which fully conformed to the Animal Welfare Act 
of the US Department of Health and Human Services. All animal procedures were conducted in 
accordance with institutional guidelines and ethical approval was obtained from the Animal Care 
and Use Committee at the West Virginia University prior to carrying out tests. 
Denervation procedure.  
To achieve compensatory hypertrophy, synergist denervation was employed.  Briefly, the 
animals were placed under a general anesthesia using 2% isoflurane, and after cessation of reflex 
activity, the medial and lateral branches of the tibial nerve that innervate the plantar flexor 
muscles (i.e. gastrocnemius and soleus) were cut, and the cut nerve ends were sutured into the 
biceps femoris muscle to ensure that the nerve stumps did not reinnervate the gastrocnemius 
muscle. Care was taken to avoid any damage to the nerves, blood vessels and connective tissues. 
Innervation to the plantaris and the deep toe flexor muscles were left intact so that the animals 
ambulated normally around the cage after the surgical denervation. Following the surgery, the 
hamstring muscle layers were closed with reabsorbable suture, and the skin incisions were closed 
with wound clips. The incision sites were covered with an antibacterial cream to prevent 
infection. This resulted in removing the enervation to both heads of the gastrocnemius muscle 
and soleus muscles and placing a compensatory load on the plantaris muscle according to our 
previously published methods (48).   
The contralateral limb received a sham surgery in which the branches of the tibial nerve 
were examined but not severed, and this served as an internal control for each animal.  All 
procedures were performed under aseptic conditions. The animals recovered quickly and were 
alert and walking within ~45 min after surgery. Loading occurred for 7 or 21 days.  In addition to 
placing a compensatory load on the plantaris muscle withdrawal of innervations to  the medial 
gastrocnemius results in an highly-favorable apoptotic environment for this muscle (49). 
BrdU implantation.   
A time-released bromodeoxyuridine (BrdU) pellet (21-day release, 0.22 µg BrdU·g body mass–
1·day–1; Innovative Research, Sarasota, FL) was placed subcutaneously on the dorsum. BrdU is 
a thymidine analog and is incorporated in nuclei during DNA synthesis. Therefore, it was used to 
identify activated satellite cells/muscle precursor cells during the 7- or 21-day period of muscle 
loading-induced hypertrophy.  
Treadmill training protocol.  
Animals were trained by running on a level motorized rodent treadmill (Columbus Instruments, 
Columbus, OH) 5 days weekly for 9 weeks. During the first 4 wk, the speed of the treadmill and 




duration of the training sessions were gradually increased from a speed of 10 m/min for 10 min 
to a running speed of 20 m/min for the OZR and 24 m/min for the LZR. Different speeds were 
used to compensate for the increased intensity of exercise for the OZR due to increased body 
weight compared to LZR.  Our pilot work suggested that the difference in body weight would 
vary around 40% and we used an estimation based on the formula of “work=1/2 mass * velocity 
squared (W=1/2m*V2)” and the estimated final weights of 500 grams for the OZR and 350 
grams for the LZR.  This calculation estimates that at 20 and 24 m/min for the OZR and LZR, 
respectively, they would have an estimated final work output of 0.028 joules. Furthermore, our 
pilot data demonstrated that these intensities would be able to be reliably maintained by the OZR 
and LZR, respectively, with minimal motivation by the investigators. Additionally, as 
demonstrated by the mitochondrial proteins examined in this study we saw similar increases in 
the trained groups of both the OZR and LZR. During weeks 5 through 9, a 5-min warm-up 
session at a speed of 15 m/min was followed by the 55-min training session. During the training 
sessions, mild electrical shock stimulation was applied, if necessary, to maintain the running 
motivation.  Animals assigned to the control group were handled daily and exposed to the noise 
of the running treadmill by placing their cages next to the treadmill during the exercise session. 
Tissue Collection.  
Animals were anaesthetized with ketamine hydrochloride, (9 mg x 100 g body weight–1) and 
xylazine hydrochloride (1 mg x 100 g body weight–1), I.P. and the hindlimb muscles from each 
limb were removed and frozen in  isopentane, cooled to the temperature of liquid nitrogen, and 
stored at -80°C until further analysis.  Additionally, a mid-belly section of each muscle was fixed 
in 10% formalin and was embedded in paraffin.  
 For examination of the muscles that underwent compensatory loading or denervation. 
The hindlimb muscles were collected seven (n=6 LZR-7 and n=6 OZR-7) and 21 days (n=6 
LZR-21 and n=6 OZR-21) after the surgical denervation. The animals were all 12 weeks old at 
time of tissue collection. The hindlimb muscles from the treadmill trained animals were harvested forty 
eight hours after the last training session and an overnight fast (~16 hours).  
These muscles were chosen to examine changes in in the oxidative (soleus), glycolytic, (plantaris), 
and mixed oxidative and glycolic (gastrocnemius) muscles. Although it has been demonstrated that there 
is a reduction in percent of total fiber area occupied by the glycolytic fibers in the OZR compared to 
the LZR, the relative percentage of the glycolytic to oxidative fibers remained constant (31).  
Torgan et al. demonstrated that the OZR has ~77% type I fibers in the soleus muscle compared 
to the LZR (~83%), with no difference in fiber type percentages in the plantaris muscle between 
the OZR and LZR (~10% type I, ~68% type IIa, and ~22% IIb). 
PROTEIN ANALYSIS.  
Immunoblot analysis   
The protein contents of the solublized extracts were quantified in duplicate by using 
bicinchoninic acid reagents (Pierce, Rockford, IL, USA) and bovine serum albumin (BSA) 
standards.  60 µg of soluble protein was boiled for 4 min at 100°C in Laemmli buffer and loaded 
on each lane of a 12% polyacrylamide gel.  The proteins were separated by routine SDS-PAGE 
for 1.5 hours at 20°C.  The gels were blotted to nitrocellulose membranes (Bio-Rad, Hercules, 




CA, USA) and stained with Ponceau S red (Sigma Chemical Co, St Louis, MO, USA) to confirm 
equal loading and transferring of proteins to the membrane in each lane. 
The membranes were then blocked in 5% non-fat milk in Tris buffered saline with 0.05% Tween 
20 (TBS-T) and then probed with appropriate primary antibody (see table 1).  Goat anti-rabbit 
secondary antibodies were conjugated to horseradish peroxidase (HRP) (Chemicon, CA, USA) 
and the signals were developed by chemiluminescence (Pierce, Rockford, IL, USA).  The signals 
were visualized by exposing the membranes to X-ray films (BioMax MS-1, Eastman Kodak, 
Rochester, NY, USA), and digital records of the films were captured with a Kodak 290 camera.  
The resulting bands were quantified as optical density (OD) x band area by a one-dimensional 
(1-D) image analysis system (Eastman Kodak, Rochester, NY, USA) and expressed in arbitrary 
units nits normalized to ß-Tublin.  The sizes of the proteins were verified by using standard 
molecular-weight markers (Bio-Rad, Hercules, CA, USA).    To reduce the day-to-day variability 
between blots all comparisons were performed on samples run on the same membrane.  
Protein Isolation 
Total Protein homogenates of whole muscle sections were prepared in lysis buffer (20 mM Tris 
pH 7.5, 150 mM NaCl, 1% Nonidet P-40, 0.5% Sodium Deoxycholate, 1 mM EDTA, 0.1% 
SDS) with the addition of Protease inhibitor cocktail (PIC; Sigma). Separate mitochondrial and 
mitochondria free protein fractions were also prepared according to methods as previously 
performed in our lab (50).  Briefly, samples were homogenized in mitochondrial isolation buffer 
(20 mM HEPES pH 7.5, 10 mM KCl, 1.5 mM MgCl2, 1 mM EGTA, 1 mM EDTA, 1 mM 
dithiothreitol, 250 mM sucrose) with protease inhibitor cocktail (Sigma-Aldrich, St Louis, MO, 
USA). The homogenates were centrifuged at 800 x g to remove nuclei and cell debris followed 
by centrifugation at 16,000 x g for 20 min at 4°C to pellet the mitochondria. The supernatants 
were used as mitochondria-free cystosol. The mitochondrial pellet was washed twice then 





Total protein homogenates of C2C12 myoblast and Myotubes were obtained by washing 3 
times in ice-cold PBS then the cells were lysed in 1x SDS sample buffer (50 mM Tris-HCl, pH 
6.8, 2% SDS, 6% glycerol, 1% β-mercaptolethanol, 0.02% bromophenol blue) was added 
directly to the myotubes. 2x SDS lysis buffer was added to an equal volume of the subcellular 
fractions obtained below.  Samples were then lysed with a 25 gauge needle and boiled for 5 min 
at 100°C and separated on a 4-12% gradient polyacrylamide gel (Invitrogen, USA).  Gels were 
blotted to nitrocellulose membranes (Bio-Rad, Hercules, CA) and stained with Ponceau red 
(Sigma Chemical Co, St Louis, MO, USA) to confirm equal loading. 
 
 Nuclear and cytoplasmic protein extracts.  
The nuclear and cytoplasmic protein extracts were obtained using the method described by 
Rothermel et al. (51) and performed routinely in our lab. For in vitro experiments cells were 
washed 3 times in ice-cold phosphate buffered saline (PBS) then incubated in lysis buffer (10 
mM NaCl, 1.5 mM MgCl2, 20 mM HEPES, pH 7.4, 20% glycerol, 0.1% Triton X-100, and 1 
mM dithiothreitol) for 5 minutes at 4ºC.  The cells were gently homogenized in a small glass 




homogenizer with Teflon pestle. For the in vivo experiments muscle samples were homogenized 
in 1:10 ice-cold lysis buffer (10 mM NaCl, 1.5 mM MgCl2, 20mM HEPES at pH 7.4, 20% 
glycerol, 0.1% Triton X-100, and 1mM dithioreitol) with a mechanical homogenizer.  Muscle 
homogenates were transferred to 1.5ml Eppendorf tubes and centrifuged at 300 rpm for 5-
minutes at 4°C. 
The homogenates were centrifuged at 1,000 rpm for 1 min at 4°C. The supernatants were 
spun twice more at 2,000 RPM and the final supernant contained the cytoplasmic protein 
fraction. The initial pellet contained the nuclear protein fraction. The nuclear pellet was washed 
twice in lysis buffer and then resuspended in lysis buffer containing 0.6 M NaCl. The mixture 
was incubated for 1 h at 4°C and centrifuged at 14,000 rpm for 15 min at 4°C. The supernatants 
contained the nuclear protein fraction. A portion of the cytosolic extract (without addition of 
protease inhibitors) was stored and used for fluorometric caspase activity assays, while protease 
inhibitor cocktail (PIC, Sigma-Aldrich, St Louis, MO) was added to the nuclear and remaining 
cytosolic portion for further analysis.   
  Mitochondrial Isolation.  
For the isolation of the mitochondrial and nuclear fraction from the cytoplasmic protein fraction 
the samples were incubated in ice-cold Mito-buffer (20 mM HEPES pH 7.5, 10 mM KCl, 1.5 
mM MgCl2, 1 mM EGTA, 1 mM EDTA, 1 mM dithiothreitol, 250 mM sucrose, and 0.1 mM 
phenylmethylsulfonyl fluoride) for 15 minutes.  The samples were homogenized by 
homogenization in a small glass homogenizer with Teflon pestle. For the in vivo experiments the 
samples were initially minced with scissors before homogenization.  The homogenates were 
centrifuged at 800 g to remove nuclei and cell debris and then centrifuged at 16,000 g for 20 min 
at 4°C to pellet the mitochondria. The supernatant contained the mitochondrial-free cytosolic 
protein fraction and this used for analysis. 




Table of immunoblot Antibodies 
 
Protein Product number Company Dilution 
    
Total Akt 9272 Cell Signaling Technology 1:2000 
Akt1 2967 Cell Signaling Technology 1:1000 
Akt2 2964 Cell Signaling Technology 1:500-1000 
Myosin Heavy Chain MF20 Hybridoma Bank 1:10000 
MyoD Sc-304 Santa Cruz 1:400 
Myogenin Sc-576 Santa Cruz 1:400 
Cyclin D 2946 Cell Signaling Technology 1:1000 
Cyclin B1 4135 Cell Signaling Technology 1:2000 
Phosph-Cyclin B1 41315 Cell Signaling Technology 1:1000 
p27 610243 BD Biosciences 1:1000 
p21 2946 Cell Signaling Technology 1:1000 
p21 Sc-6246 Santa Cruz 1:400 
p53 Sc-99 Santa Cruz 1:400 
Mn SOD 06-984 Upstate 1:2000 
Cu/Zn SOD 07-403 Millipore 1:1000 
COX I A6403 Invitrogen 1:1000 
Beta-tubulin Ab6046 Abcam 1:2000 
Smac/Diablo 612244 BD Biosciences 1:500 
AIF 4642 Cell Signaling Technology 1:1000 
UCP3 UCP32-A Alpha Diagnostics 1:1000 
Bax Sc-493 Santa Cruz 1:400 
Bcl-2 sc-7382 Santa Cruz 1:400 
BAD Sc-943 Santa Cruz 1:400 
FoxO3a 9467 Cell Signaling Technology 1:1000 
FoxO1 9454S Cell Signaling Technology 1:1000 
FoxO4 9472 Cell Signaling Technology 1:1000 
Histone 07-371 Upsate 1:3000 
 
 





Bax and Bcl-2 binding.   
To determine if Bax to Bcl-2 binding corresponded to Akt Ser473 phosphorylation, FFA treated 
myotubes were serum starved for two hours with or without the addition FFAs or a commercially 
available Akt inhibitor (124005, Calbiochem, Germany). 1% FBS was reintroduced to the media 
10 minutes before collection of the myotubes.  Similarly, to determine if the binding of Bax to 
Bcl-2 was altered with palmitate treatment, Bcl-2 was immunoprecipitated and the binding of 
Bax was determined through immunoblot analysis.  
After treatment, myotubes were harvested in CHAPS buffer (40 mM HEPES, pH 7.5, 120 
mM NaCl, 1 mM EDTA, 10 mM pyrophosphate, 10 mM -glycerolphosphate, 40 mM NaF, 1.5 
mM sodium vanadate, 0.3% CHAPS, 0.1 mM PMSF, 1 mM benzamidine, and 1 mM DTT), 
rocked for 20 min at 4°C and then centrifuged at 1,000 g for 10 min at 4°C. An aliquot from the 
resulting supernatant was preserved as total protein.  The remaining supernatant was incubated 
with anti-Bcl-2 (0.2 µg/100 µl; Santa Cruz), and incubated overnight at 4°C. Prior to analysis, the 
immune complexes were collected for 1 h at 4°C with a goat anti-mouse BioMag IgG (Quigen, 
310004) beads, blocked with 0.1% nonfat dry milk in CHAPS buffer.  The beads were collected 
using a magnetic stand and washed with 200 mM CHAPS and 60 mM HEPES. The precipitates 
were eluted in 5x SDS sample buffer (250 mM Tris-HCl pH 6.8, 10% SDS, 30% Glycerol, 5% 
β-mercaptoethanol and 0.02% bromophenol blue) and then boiled for 5 min. The beads were 
collected with a magnetic stand, and the supernatant was collected and subjected to SDS-PAGE.  
 
IMMUNOFLUORESCENT STAINING.  
BrdU. 
Parafin embedded, 7-µm-thick, muscle cross sections from the loaded and control plantaris 
muscles were de-paraffinized in xylene, followed by rehydration in graded ethanol washes, and 
then rinsed in distilled H2O.  The tissues sections were incubated in an antigen retrieval buffer 
(10mM sodium citrate, 0.05% Tween-20, ph 6.0) for 30 minutes at 95ºC, washed in phosphate 
buffered saline (PBS) and then blocked in 1.5% goat serum in PBS at 37ºC for 30 min. Sections 
were then incubated with an anti-BrdU mouse monoclonal antibody (1:20 dilution, 555627; BD 
Pharmingen, San Diego, CA) followed by an anti-mouse Alexa 488 (A21463; Invitrogen, CA). 
Negative control experiments were done by omitting the BrdU antibody from the tissue sections. 
The basal lamina was identified with primary antibodies to anti-Laminin mouse IgG2a (D18; 
Hybridoma Bank) followed by goat anti-mouse IgG2a-R (Santa Cruz Biotechnology, CA). Only 
the BrdU positive nuclei within the basal lamina were quantified. The BrdU labeling index were 
calculated as: the number of BrdU labeled nuclei. total nuclei-1.100. This  provided an index of 
satellite cell activation. 
PAX7 
Pax7 antibody (PAX7; Developmental Studies, Hybridoma Bank, U. Iowa) was used to 
determine the number of satellite cells in the control muscles (52). Since the formalin fixation 




interfered with the Pax7 antibody, 7µm cross-sections were obtained from frozen mid-belly 
sections of the muscle as previously performed in our laboratory (53). Briefly, the sections were 
air dried at room temperature, fixed in ice-cold methanol-acetone (1:1) for 10 minutes, rinsed in 
PBS, and permeablized in 0.2% triton-X in 0.1% sodium citrate. Next the sections were 
incubated for 30 minutes in 1.5% goat serum at 37ºC in before incubation with Pax7 primary 
antibodies, followed by an anti-mouse Alexa 488. The samples were then probed with anti-
Laminin mouse IgG2a (2E8; Hybridoma Bank) followed by goat anti-mouse IgG2a-R (Santa 
Cruz Biotechnology, CA). 
D18, developed by Dr. Joshua Sanes, PAX7 antibody, developed by Dr. Atsushi Kawakami, and 
2E8, developed by Dr. Eva Engvall, antibodies were obtained from the Developmental Studies 
Hybridoma Bank developed under the auspices of the NICHD and maintained by The University 
of Iowa, Department of Biological Sciences, Iowa City, IA 52242.  
TUNEL. 
In situ TdT-mediated dUTP nick end labeling (TUNEL) staining.  The nuclei with DNA strand 
breaks were assessed using a fluorometric TUNEL detection kit according to the manufacturer’s 
instructions for both C2C12 cells and muscle cross sections (1684795; Roche Applied Science, 
Indianapolis, IN).  For muscle cross sections, 10-μm-thick frozen medial gastrocnemius muscle 
cross sections from were cut in a freezing cryostat at -20°C. Tissue sections were air dried at 
room temperature, fixed in 4% paraformaldehyde in PBS, pH 7.4, at room temperature for 20 
min, permeabilized with 0.2% Triton X-100 in 0.1% sodium citrate at 4°C for 2 min, and 
incubated with fluorescein-conjugated TUNEL reaction mixture in a humidified chamber at 
37°C for 1 h in the dark. Negative control experiments were done by omitting the TdT enzyme in 
the TUNEL reaction mixture on the tissue sections. After TUNEL labeling, the muscle sections 
were incubated with an anti-chick laminin mouse monoclonal antibody (for visualizing the basal 
lamina, 20 μg/ml, clone 31–2) followed by an anti-mouse (1:200 dilution, C2181) and mounted 
with DAPI Vectashield mounting medium.  TUNEL- and DAPI-positive nuclei and laminin 
staining were examined under a fluorescence microscope, and the captured images were stacked 
using a SPOT RT camera (Diagnostic Instruments, Sterling Heights, MI), and SPOT RT 
software (Universal Imaging, Downingtown, PA). The numbers of TUNEL and DAPI-positive 
nuclei were counted from six random, nonoverlapping fields at an objective magnification of 
x40. Only the labeled nuclei that were under the laminin staining were counted, to exclude any 
non-muscle nuclei in the sections. Data were expressed as number of TUNEL-positive nuclei per 
100 nuclei counted.  






Akt/PKB Activity Assay.   
To confirm changes to Akt/PKB activity another group of C2C12 myotubes from each 
treatment condition were incubated in serum free DMEM for 2 hours with the addition of 100 
nM insulin for 10 minutes before collection (46;47).  Akt/PKB activity was assessed via 
Akt/PKB Kinase Activity Kit (Stressgen, EKS-400A).  The change in color was measured at a 
wavelength of 405 nm by using a Dynex MRX plate reader controlled through PC software 
(Revelation; Dynatech Laboratories, CA, USA). Measurements were performed in duplicate, 
with all samples analyzed at the same time. The OD405 reading was then normalized to the 
milligrams of protein used in the assay.  
Cytochrome c Assay.   
The mitochondria free cytoplasmic fraction protein obtained as described previously was 
used for analysis of the cytochrome-c released from the mitochondria according to the 
manufacture’s instructions (#5265, Medical and Biological Laborotories).  The change in color 
were monitored at a wavelength of 450 nm using a Dynex MRX plate reader. Measurements 
were performed in duplicate with all comparisons performed with the same assay.  The 
cytochrome c content were expressed as OD450 per milligram of protein. 
 
Fluorometric caspase activity assay.  
 Activity of the caspase-9, 3, and 8 were analyzed by a commercial caspase assay kit (APO-
54A-019-KI01, Apotech, Switzerland) according to the manufacturer’s procedure and as 
previously performed in our laboratory (54).  Caspase-3 and caspase-9 were measured as indices 
of mitochondrial induced apoptosis, whereas caspase 8 is a non-mitochondrial dependent 
caspase. Briefly, 50 µl of the nuclei-free cytosolic extract (without protease inhibitors) were 
incubated in 50 µl of assay buffer (50 mM PIPES, 0.1 mM EDTA, 10% glycerol, 10 mM DTT, 
pH 7.2) with 100 µM of the fluorogenic 7-amino-4-trifluoromethyl coumarin (AFC)-conjugated 
substrate (Ac-DEVD-AFC, Alexis Corp., San Diego, CA, USA) at 37°C for 2 h. Caspase activity 
were accessed using a fluorescent microplate reader at the following wavelengths: caspase-8 
excitation 380nm and emission 460nm; caspase-3 & 9 excitation 400nm and emission 505nm.  
The microplate were incubated at 37°C for 2-hours with caspase activity determined by 
subtracting OD readings at time 2-hour from the initial reading at time 0-hour.  Optical density 
were normalized to the protein concentration of each muscle sample to provide a caspase activity 
index (OD . mg protein-1).  Measurements were performed in duplicate. 
 
 
DNA fragmentation.   
A cell death detection ELISA kit (Roche Applied Science, Indianapolis, IN, USA) was used 
to quantitatively determine the apoptotic DNA fragmentation by measuring the cytosolic histone-




associated mono- and oligonucleosomes. The change in optical density (OD) was measured at a 
wavelength of 450 nm by using a Dynex MRX plate reader controlled through PC software 
(Revelation; Dynatech Laboratories, CA, USA). Measurements were performed in duplicate, 
with samples from OZR and LZR analyzed at the same time. The OD450 reading was then 
normalized control samples. Measurements were performed in triplicate. 
STATISTICAL ANALYSES  
Statistical analyses were performed using the SYSTAT 11.0 software package. A one 
way Analysis of variance (ANOVA) was performed on the difference in all measured variables.   
Statistical significance was accepted at P < 0.05. All data are given as means + standard error. 
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